

ULUSOY UN SANAYİ VE TİCARET A.Ş.

CONSOLIDATED FINANCIAL STATEMENTS AND FOOTNOTES FOR
THE INTERIM PERIOD JANUARY 1–MARCH 31, 2021

CONTENTS	Page
CONSOLIDATED STATEMENT OF FINANCIAL POSITION FOR THE INTERIM PERIOD	1 – 2
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE INTERIM PERIOD	3
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE INTERIM PERIOD	4
CONSOLIDATED CASH FLOW STATEMENT FOR THE INTERIM PERIOD	5
EXPLANATORY NOTES FOR THE CONSOLIDATED FINANCIAL STATEMENTS	
FOOTNOTE 1 GROUP'S ORGANIZATION AND FIELD OF ACTIVITY	6-8
FOOTNOTE 2 GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS	9-22
FOOTNOTE 3 REPORTING BY SEGMENTS	23-24
FOOTNOTE 4 CASH AND CASH EQUIVALENTS	25
FOOTNOTE 5 FINANCIAL INVESTMENTS	25
FOOTNOTE 6 FINANCIAL BORROWING	26-28
FOOTNOTE 7 TRADE RECEIVABLES AND PAYABLES	29
FOOTNOTE 8 OTHER RECEIVABLES AND PAYABLES	30
FOOTNOTE 9 DERIVATIVE INSTRUMENTS	30-31
FOOTNOTE 10 INVENTORIES	31
FOOTNOTE 11 PREPAID EXPENSES AND DEFERRED INCOME	32
FOOTNOTE 12 INVESTMENTS VALUED BY EQUITY METHOD	32-33
FOOTNOTE 13 INVESTMENT PROPERTIES	34
FOOTNOTE 14 ASSETS RELATED TO CURRENT PERIOD TAX	35
FOOTNOTE 15 RIGHT-OF-USE ASSETS	35
FOOTNOTE 16 PROPERTY, PLANT AND EQUIPMENT	36-37
FOOTNOTE 17 INTANGIBLE ASSETS	38
FOOTNOTE 18 PROVISIONS, CONTINGENT ASSETS AND LIABILITIES	39-40
FOOTNOTE 19 PROVISIONS RELATED TO EMPLOYEE BENEFITS	40-41
FOOTNOTE 20 OTHER ASSETS AND LIABILITIES	42
FOOTNOTE 21 EQUITIES	43-45
FOOTNOTE 22 REVENUES AND COST OF SALES	46
FOOTNOTE 23 OVERHEAD EXPENSES AND MARKETING COSTS	47-48
FOOTNOTE 24 OTHER OPERATING INCOME AND EXPENSES	49
FOOTNOTE 25 INCOME FROM INVESTING ACTIVITIES	50
FOOTNOTE 26 FINANCE INCOME AND EXPENSES	50
FOOTNOTE 27 INCOME TAXES	51-54
FOOTNOTE 28 EARNINGS PER SHARE	54
FOOTNOTE 29 RELATED PARTY DISCLOSURES	55-57
FOOTNOTE 30 NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS	58-62
FOOTNOTE 31 FINANCIAL INSTRUMENTS (FAIR VALUE DISCLOSURES AND OTHER DISCLOSURES CONCERNING HEDGE ACCOUNTING)	63
FOOTNOTE 32 EVENTS AFTER THE REPORTING PERIOD	63

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (BALANCE SHEET)
FOR THE INTERIM PERIOD AS OF MARCH 31, 2021

(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)

	Footnote No	Current Period	Previous Period
		Unaudited	Independently Audited
Type of Financial Statement		Consolidated	Consolidated
Period		March 31, 2021	December 31, 2020
ASSETS			
Current Assets		1,953,612,938	1,339,099,007
Cash and Cash Equivalents	4	457,079,438	327,845,182
Financial Investments	5	65,334,830	32,104,780
Trade Receivables		805,428,043	430,505,817
- Trade Receivables from Related Parties	7, 29	1,476,834	1,384,711
- Trade Receivables from Unrelated Parties	7	803,951,209	429,121,106
Other Receivables		9,512,419	15,144,060
- Other Receivables from Unrelated Parties	8	9,512,419	15,144,060
Derivative Instruments	9	56,383,954	10,668,553
Inventories	10	383,079,457	459,113,825
Prepaid Expenses	11	158,810,250	48,896,941
Assets Related To Current Period Tax	14	1,543,726	1,262,430
Other Current Assets	20	16,440,821	13,557,419
Non-current Assets		343,878,586	334,240,587
Trade Receivables		10,197,097	10,197,097
- Trade Receivables from Unrelated Parties	7	10,197,097	10,197,097
Other Receivables		284,414	285,615
- Other Receivables from Unrelated Parties	8	284,414	285,615
Investments Valued by Equity Method	12	5,109,026	4,936,299
Investment Properties	13	12,863,685	12,863,685
Right-of-use Assets	15	2,039,872	2,395,579
Property, Plant and Equipment	16	292,685,594	285,597,731
Intangible Assets	17	1,609,282	1,356,251
Prepaid Expenses	11	821,623	3,042,014
Deferred Tax Assets	27	18,267,993	13,566,316
TOTAL ASSETS		2,297,491,524	1,673,339,594

The attached footnotes constitute an integral part of these consolidated financial statements.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (BALANCE SHEET)
FOR THE INTERIM PERIOD AS OF MARCH 31, 2021

(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)

Type of Financial Statement Period	Footnote No	Current Period	Previous Period
		Unaudited Consolidated March 31, 2021	Independently Audited Consolidated December 31, 2020
LIABILITIES			
Short-term Liabilities		1,599,422,979	973,418,067
Short-term Borrowings		640,742,553	340,126,709
- Bank Loans	6	640,742,553	340,126,709
Short-term Portions of Long-term Borrowings	6	209,368,518	185,994,988
Trade Payables		662,514,434	392,005,623
- Trade Payables to Related Parties	7, 29	5,437,067	89,877
- Trade Payables to Unrelated Parties	7	657,077,367	391,915,746
Payables Related to Employee Benefits	19	2,686,944	1,818,309
Other Payables		15,078,921	15,479,323
- Other Payables to Related Parties	8, 29	14,592,129	14,959,964
- Other Payables to Unrelated Parties	8	486,792	519,359
Derivative Instruments	9	15,157,538	2,017,984
Deferred Income	11	33,474,212	20,913,623
Tax Liability for the Current Period Profit	27	-	61,225
Short-term Provisions		7,133,657	6,613,745
- Short-term Provisions Related to Employee Benefits	19	941,588	45,101
- Other Short-term Provisions	18	6,192,069	6,568,644
Other Short-term Liabilities	20	13,266,202	8,386,538
Long-term Liabilities		292,827,815	315,413,045
Long-term Borrowings	6	262,368,004	293,157,916
Long-term Provisions		2,943,671	2,564,363
- Long-term Provisions Related to Employee Benefits	19	2,943,671	2,564,363
Deferred Tax Liability	27	27,516,140	19,690,766
Total Equity		405,240,730	384,508,482
Paid-in Capital		190,970,000	84,500,000
Premiums (Discounts) Related to Shares		15,269,029	57,194,029
Other Comprehensive Income (Expenses) not to be Reclassified to Profit or Loss		61,342,033	61,443,837
Revaluation and Measurement Earnings/Losses		61,342,033	61,443,837
- Increases/Decreases in Property, Plant and Equipment Due to Revaluation		62,149,360	62,149,360
- Revaluation Gains on Defined Benefit Plans		(807,327)	(705,523)
Other Comprehensive Income (Expenses) to be Reclassified to Profit or Loss		24,725,806	15,353,588
- Foreign Currency Exchange Differences		24,725,806	15,353,588
Reserves on Retained Earnings		10,102,037	7,726,207
Retained Earnings or Losses		91,369,991	115,008,531
Net Profit or Loss for the Period		11,461,834	43,282,290
Parent Company Equity		405,240,730	384,508,482
Non-Controlling Interests		-	-
TOTAL LIABILITIES AND EQUITY		2,297,491,524	1,673,339,594

The attached footnotes constitute an integral part of these consolidated financial statements.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE INTERIM PERIOD JANUARY 1–MARCH 31, 2021

(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)

Type of Financial Statement	Footnote No	Current Period	Previous Period
		Unaudited	Unaudited
Period		Consolidated	Consolidated
		January 1 - March 31, 2021	January 1 - March 31, 2020
Revenue	22	1,475,836,844	1,059,107,296
Cost of Sales	22	(1,402,569,074)	(997,286,076)
GROSS PROFIT/LOSS		73,267,770	61,821,220
Overhead Expenses	23	(9,130,963)	(5,039,028)
Marketing Expenses	23	(24,946,292)	(13,057,053)
Research and Development Expenses	23	(13,116)	(45,073)
Other Operating Income	24	75,483,143	48,794,884
Other Operating Expenses	24	(34,867,467)	(15,446,333)
OPERATING PROFIT/LOSS		79,793,075	77,028,617
Income from Investing Activities	25	283,538	390,103
Cancelled Impairment Earnings and Losses Determined as per TFRS 9	25	(266,588)	(196,760)
Shares from Profits (Losses) of Investments Valued by Equity Method	12	172,727	227,214
OPERATING PROFIT/LOSS BEFORE FINANCE EXPENSES		79,982,752	77,449,174
Finance Income	26	85,688,983	45,821,776
Finance Expenses	26	(150,404,254)	(97,251,829)
PROFIT/LOSS BEFORE TAX FROM CONTINUING OPERATIONS		15,267,481	26,019,121
Tax Expense/Income from Continuing Operations		(3,805,647)	(6,586,341)
Tax Expense/Income for the Period	27	(651,541)	(2,022,467)
Deferred Tax Expense/Income	27	(3,154,106)	(4,563,874)
PROFIT (LOSS) FOR THE PERIOD		11,461,834	19,432,780
Distribution of the Profit (Loss) for the Period		11,461,834	19,432,780
Parent Company Shares		11,461,834	19,432,780
Earnings (Losses) per Share		0.0600	0.2356
Earnings per Share from Continuing Operations	28	0.0600	0.2356
OTHER COMPREHENSIVE INCOME (EXPENSES)		9,270,414	39,339,255
Other Income not to be Reclassified to Profit or Loss		(132,213)	43,838,955
Increases/Decreases in Property, Plant and Equipment Due to Revaluation		-	43,735,705
Revaluation Gains (Losses) on Defined Benefit Plans		(132,213)	103,250
Taxes Related to Other Comprehensive Income not to be Reclassified to Profit or Loss		30,409	(9,644,570)
Revaluation Gains (Losses) on Defined Benefit Plans, Tax Effect		30,409	(22,715)
Increases (Decreases) in Property, Plant and Equipment Due to Revaluation		-	(9,621,855)
Other Income to be Reclassified to Profit or Loss		9,372,218	5,144,870
Foreign Currency Exchange Differences		9,372,218	5,144,870
Taxes Related to Other Comprehensive Income to be Reclassified to Profit or Loss		-	-
Deferred Tax Expense/Income		-	-
TOTAL COMPREHENSIVE INCOME (EXPENSES)		20,732,248	58,772,035
Distribution of Total Comprehensive Income		20,732,248	58,772,035
Non-Controlling Interests		-	-
Parent Company Shares		20,732,248	58,772,035

The attached footnotes constitute an integral part of these consolidated financial statements.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE INTERIM PERIOD JANUARY 1–MARCH 31, 2021

(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)

	Footnote No.	Paid-in Capital	Reacquired Shares	Share Issuance Premiums/Discounts	Other Accumulated Comprehensive Income or Expenses not to be Reclassified to Profit or Loss		Other Accumulated Comprehensive Income or Expenses to be Reclassified to Profit or Loss	Retained Earnings		Equities	
					Increases/Decreases in Property, Plant and Equipment Due to Revaluation	Revaluation Gains (Losses) on Defined Benefit Plans	Foreign Currency Exchange Differences	Reserves on Retained Earnings	Retained Profits/Losses		Net Profit/Loss for the Period
Balances as of 01.01.2020		84,500,000	(3,445,108)	38,607,992	27,202,058	(600,430)	4,346,131	11,171,315	84,516,493	26,995,351	273,293,802
Transfers									26,995,351	(26,995,351)	-
Total Comprehensive Income (Expenses)					34,113,850	80,535	5,144,870			19,432,780	58,772,035
- Profit (Loss) for the Period										19,432,780	19,432,780
- Other Comprehensive Income (Expenses)					34,113,850	80,535	5,144,870				39,339,255
Balances as of 31.03.2020	21	84,500,000	(3,445,108)	38,607,992	61,315,908	(519,895)	9,491,001	11,171,315	111,511,844	19,432,780	332,065,837
Balances as of 01.01.2021		84,500,000	-	57,194,029	62,149,360	(705,523)	15,353,588	7,726,207	115,008,531	43,282,290	384,508,482
Transfers								2,375,830	40,906,460	(43,282,290)	-
Total Comprehensive Income (Expenses)						(101,804)	9,372,218			11,461,834	20,732,248
- Profit (Loss) for the Period										11,461,834	11,461,834
- Other Comprehensive Income (Expenses)						(101,804)	9,372,218				9,270,414
Capital Increase		106,470,000		(41,925,000)					(64,545,000)		-
Balances as of 31.03.2021	21	190,970,000	-	15,269,029	62,149,360	(807,327)	24,725,806	10,102,037	91,369,991	11,461,834	405,240,730

The attached footnotes constitute an integral part of these consolidated financial statements.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ
CONSOLIDATED CASH FLOW STATEMENT
FOR THE INTERIM PERIOD JANUARY 1–MARCH 31, 2021

(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)

Type of Financial Statement	Footnote No	Current Period	Previous Period
		Unaudited	Unaudited
Period		Consolidated	Consolidated
		January 1 - March 31, 2021	January 1 - March 31, 2020
Cash Flows from Operating Activities		(143,058,737)	126,158,149
Profit (Loss) for the Period		11,461,834	19,432,780
- Profit (Loss) for the Period from Continuing Operations	21	11,461,834	19,432,780
Adjustments Related to Net Profit (Loss) Reconciliation for the Period		(4,152,618)	10,280,709
- Adjustments Related to Depreciation and Amortization Expenses	16, 17	6,378,260	2,333,425
- Adjustments Related to Provisions	19	(11,426,094)	764,028
- Adjustments Related to Interest Income (Expenses)	26	(2,258,890)	2,619,383
- Adjustments Related to Tax (Income) Expenses	27	3,154,106	4,563,873
Changes in Working Capital		(150,367,953)	96,444,660
- Adjustments Related to Decreases (Increases) in Trade Receivables	7, 29	(368,645,469)	(44,424,007)
- Adjustments Related to Decreases (Increases) in Other Receivables Related to Operations	8, 29	5,632,842	(1,753,818)
- Adjustments Related to Increases (Decreases) in Inventories	10	82,159,724	61,232,447
- Adjustments Related to Increases (Decreases) in Trade Payables	7, 29	264,032,839	206,676,551
- Adjustments Related to Increases (Decreases) in Other Payables Related to Operations	8, 29	468,232	(640,314)
- Adjustments Related to Other Increases (Decreases) in Working Capital		(134,016,121)	(124,646,199)
Cash Flows from Investing Activities		(40,088,240)	(27,898,293)
Cash Inflows from Sale of Shares of Other Entities or Funds or Debt Instruments		-	51,653
Cash Inflows from Sale of Property, Plant and Equipment and Intangible Assets		194,670	173,191
- Cash Inflows from Sale of Property, Plant and Equipment	16	194,670	173,191
Cash Outflows to Purchase of Property, Plant and Equipment and Intangible Assets		(13,423,684)	(3,871,810)
- Cash Outflows to Purchase of Property, Plant and Equipment	16	(13,068,474)	(3,871,810)
- Cash Outflows to Purchase of Intangible Assets	17	(355,210)	-
Cash Outflows from Derivative Financial Instruments		(26,859,226)	(24,251,327)
Cash Flows from Financing Activities		303,009,015	93,376,522
Cash Inflows from Borrowing		386,153,721	161,414,367
- Cash Inflows from Loans	6	386,153,721	161,414,367
Cash Outflows Related to Debt Repayments		(65,557,519)	(57,942,589)
Cash Outflows Related to Debt Payments Arising from Lease Contracts	13, 6	(490,142)	-
Paid Interest	26	(19,294,140)	(12,156,965)
Interest Earned	26	2,197,095	2,061,709
Net Increases (Decreases) in Cash and Cash Equivalents Before		119,862,038	191,636,378
the Effect of Foreign Currency Exchange Differences			
The Effect of Foreign Currency Exchange Differences on Cash and Cash Equivalents		9,372,218	5,144,870
Net Increases (Decreases) in Cash and Cash Equivalents		129,234,256	196,781,248
Cash and Cash Equivalents at the Beginning of the Period	4	327,845,182	148,566,399
Cash and Cash Equivalents at the End of the Period	4	457,079,438	345,347,647

The attached footnotes constitute an integral part of these consolidated financial statements.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 1- GROUP'S ORGANIZATION AND FIELD OF ACTIVITY

Ulusoy Un Sanayi ve Ticaret Anonim Şirketi ("Company") was established in 1989 to manufacture, trade in, import and export any foodstuff made of grains and legumes, such as flour, semolina, pasta and biscuits.

The headquarters of the Company is in Hançerli Mahallesi Necipbey Caddesi No:107 İlkadım, Samsun. The address of the Company's production plant in Samsun is Şabanoğlu Mahallesi Atatürk Bulvarı No:180/1 Tekkeköy, Samsun. The address of its production plant in Çorlu is Hıdırağa Mahallesi İstasyon Caddesi No: 20 Çorlu, Tekirdağ.

The Company's authorized capital is 422,500,000 TRY. The authorized capital permission granted by the Capital Markets Board ("CMB") is valid for the period 2020–2024 (5 years).

On 12-13-14 November 2014, the public offering of Ulusoy Un Sanayi ve Ticaret A.Ş. by book building method was authorized by the CMB at the meeting no. 32/1095 on November 7, 2014. The shares with a nominal value of 23,500,000 TRY offered to the public through capital increase and shareholder sales were sold in their entirety.

The issued capital of the Company as of March 31, 2021 is 190,970,000 TRY. (one hundred ninety million nine hundred seventy thousand Turkish liras) This capital is divided into a total of 190,970,000 shares each with nominal value of 1 TRY, namely 22,035,000 Group A shares, 14,690,000 Group B shares and 154,245,000 Group C shares. Group A and B shares are registered, while the part of the Group C shares listed in Borsa Istanbul is bearer shares and the other part is registered shares. In the election of Group A shares' Board of Directors, Group A and B shares have voting privileges at the General Assembly. At least two members in case of a Board of Directors consisting of five members, at least three members in case of a Board of Directors consisting of six or seven members, at least four members in case of a Board of Directors consisting of eight or nine members, and at least five members in case of a Board of Directors consisting of ten or eleven members, excluding independent members, are elected among candidates to be nominated by the majority of Group A shareholders. Group A, Group B and Group C shareholders or their agents present at the Ordinary and Extraordinary General Assembly meetings have 15 (fifteen), 10 (ten) and 1 (one) voting rights for each share, respectively.

The number of personnel employed in the Company as of March 31, 2021 is 303 (December 31, 2020: 298 personnel).

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 1 - GROUP'S ORGANIZATION AND FIELD OF ACTIVITY (Continued)**

The Company's capital distribution as of March 31, 2021 is as follows:

Shareholders	Number of Shares	Group	Percentage (%)	Amount
Fahrettin Ulusoy	10,283,000	A	5.38	10,283,000
	4,407,000	B	2.31	4,407,000
	-	C	-	-
	14,690,000		7.69	14,690,000
Nevin Ulusoy	1,469,000	A	0.77	1,469,000
	2,938,000	B	1.54	2,938,000
	27,589,237	C	14.45	27,589,237
	31,996,237		16.76	31,996,237
Onur Erhan Ulusoy	1,469,000	A	0.77	1,469,000
	4,407,000	B	2.31	4,407,000
	23,478,668	C	12.29	23,478,668
	29,354,668		15.37	29,354,668
Eren Günhan Ulusoy	8,814,000	A	4.62	8,814,000
	2,938,000	B	1.54	2,938,000
	37,925,691	C	19.86	37,925,691
	49,677,691		26.02	49,677,691
Mithat Denizcigil	215,518	C	0.11	215,518
	215,518		0.11	215,518
Kâmil Adem	60,887	C	0.03	60,887
	60,887		0.03	60,887
Publicly-held	64,975,000	C	34.02	64,975,000
Total	190,970,000		100.00	190,970,000

Subsidiaries

The Company's subsidiaries as of March 31, 2021 and December 31, 2020 are as follows:

Subsidiaries	Shareholding Percentages (%)	
	March 31, 2021	December 31, 2020
Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.	100	100
GK Tarım Ürünleri Lisanslı Depoculuk A.Ş.	100	100
Rolweg SA	100	100
Alfaway Gıda Sanayi ve Ticaret A.Ş.	100	100

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 1 - GROUP'S ORGANIZATION AND FIELD OF ACTIVITY (Continued)

Disclosures Concerning the Subsidiaries' Field of Activity

Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.

Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş. ("Uludaş") was established on February 27, 2015 to provide licensed warehousing services for storage of agricultural products under healthy conditions.

The headquarters of Uludaş is located in Şabanoğlu Mahallesi Atatürk Bulvarı No:180-1 Tekkeköy, Samsun. It has 18 personnel as of March 31, 2021. (December 31, 2020: 21 personnel)

As of March 31, 2021 and December 31, 2020, its capital is 25,000,000 TRY and it does not have any outstanding capital.

Uludaş acquired 100% of the shares of GK Tarım Ürünleri Lisanslı Depoculuk A.Ş. ("GK Tarım") in July 2020. The financial statements of Uludaş as of March 31, 2021 and December 31, 2020 were prepared in consolidation with GK Tarım.

Rolweg SA

Rolweg SA was established on March 15, 2018 to trade in grains with a capital of 1,000,000 CHF. 100% of Rolweg SA's capital is owned by Ulusoy Un Sanayi ve Ticaret A.Ş. Rolweg SA's headquarters is in Rue du Nant6, 1207 Geneva, Switzerland. Rolweg SA's capital was increased to 2,000,000 CHF on July 23, 2019. As of March 31, 2021 and December 31, 2020, Rolweg SA's capital is 3,000,000 CHF.

Alfaway Gıda Sanayi ve Ticaret A.Ş.

Alfaway Gıda Sanayi ve Ticaret A.Ş., ("Alfaway") was established on September 24, 2019 to engage in manufacture, retail and wholesale trade, import and export of any foodstuff. The headquarters of Alfaway is located in Şabanoğlu Mahallesi Atatürk Bulvarı No:180/1 Tekkeköy, Samsun.

Its capital as of March 31, 2021 and December 31, 2020. is 5,000,000 TRY. It has 53 personnel as of March 31, 2021. (December 31, 2020: 58 personnel)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS

2.1 Guidelines for Presentation

The Group prepared its consolidated financial statements for the interim period ended March 31, 2021 in accordance with the requirements of TAS 34 "Interim Financial Reporting" within the framework of CMB Communiqué Serial II, No: 14.1 and its explanatory comments. Financial statements are prepared based on the Turkish Financial Reporting Standards ("TFRS") issued by the Public Oversight, Accounting and Auditing Standards Authority ("POA") under Article 5 of the Communiqué. The TFRS include the Standards and Interpretations issued by the POA as Turkish Accounting Standards ("TAS"), Turkish Financial Reporting Standards, Interpretations of TAS and Interpretations of the TFRS.

Interim consolidated financial statements are presented in accordance with the formats specified in the TFRS Taxonomy issued by POA on April 15, 2019 and the Financial Statement Examples and Guidelines issued by the CMB.

The Group maintains its accounting records and statutory financial statements in Turkish lira ("TRY") in accordance with the requirements of the applicable commercial legislation and financial legislation in Turkey as well as the Uniform Chart of Accounts ("UCA") published by the Ministry of Finance. The Subsidiary operating in foreign countries prepared its statutory financial statements in compliance with the laws and regulations of the countries in which it operates.

The interim condensed financial statements of the Company prepared as of March 31, 2021 were approved by the Company Management on May 12, 2021. The General Assembly is authorized to make amendments to the financial statements after their publication.

Valid and reporting currency

The Group's consolidated financial statements for the interim period are presented in TRY, the functional and presentation currency. The assets and liabilities in the financial statements of the subsidiary operating in the foreign country, prepared in USD, were converted into TRY based on the exchange rate on the date of the balance sheet, whereas its income and expenses were converted based on the average exchange rate. The exchange differences arising from the use of the closing and average exchange rates are kept track of under the changes in foreign exchange rates.

Adjustments to Financial Statements in Hyperinflation Periods

As per the decision taken on March 17, 2005, the CMB announced that as from January 1, 2005, no inflation accounting application is required for publicly-held companies operating in Turkey. The interim consolidated financial statements of the Group were prepared within the framework of the said decision.

Netting/Offsetting

Financial assets and liabilities are presented as net values in cases where there is a legal claim or an intention to evaluate the assets and liabilities as net values, or where the acquisition of the assets and the fulfillment of the liabilities succeed each other.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.1 Guidelines for Presentation (Continued)

Consolidation Guidelines

a) Subsidiaries

Consolidated financial statements include the financial statements of the Company and its subsidiaries. The Company is deemed to have control over its subsidiaries if it meets the following conditions:

- Having influence over the investee;
- Being open or entitled to the variable returns to be obtained from the investee;
- Being able to exercise its control over the returns.

In cases where the company does not have the majority voting right over the investee, it has controlling interest in the investee if it has sufficient voting rights to direct the activities of the relevant investment alone.

The company considers all relevant events and conditions, including the following, in assessing whether the majority of the votes in the relevant investee is sufficient to have controlling interest:

- Comparing the voting right of the company with the voting rights of other shareholders;
- Potential voting rights owned by the company and other shareholders;
- Rights arising from other contracts;
- Other events and conditions that may show whether the Company currently has interest in managing the relevant activities (including voting at the general assembly meetings in previous periods) in cases where a decision is required.

Should any situation or event that may cause change in any of the abovementioned criteria occur, the Company reevaluates whether it has controlling interest in its investee.

Inclusion of a subsidiary in the scope of consolidation starts with the Company gaining control over the subsidiary and ends with the loss of this control. Income and expenses of the subsidiaries acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date of acquisition to the date of disposal.

The Subsidiaries' statements of financial position and statements of profit or loss and other comprehensive income were consolidated using the full consolidation method.

Each item of consolidated profit or loss and other comprehensive income belongs to the parent company shareholders and non-controlling interests. Even if non-controlling interests result in red balance, total consolidated profit or loss and other comprehensive income of subsidiaries are transferred to parent company shareholders and non-controlling interests.

Where necessary, adjustments regarding the accounting policies were made in the financial statements of the subsidiaries to ensure uniformity with the accounting policies followed by the Group.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)****2.1 Guidelines for Presentation (Continued)****Consolidation Guidelines (Continued)****a) Subsidiaries (Continued)**

All intragroup assets and liabilities, equity, income and expenses and cash flows from transactions between Group companies are eliminated in the consolidation process.

Shareholding percentages of the subsidiaries controlled by the Company as of March 31, 2021 and December 31, 2020 are as follows:

Subsidiaries	Shareholding Percentages (%)	
	March 31, 2021	December 31, 2020
Uludağ Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.	100	100
GK Tarım Ürünleri Lisanslı Depoculuk A.Ş.	100	100
Rolweg SA	100	100
Alfaway Gıda Sanayi ve Ticaret A.Ş.	100	100

b) Affiliates

Affiliates are recognized by equity method. They are entities where the Group has 20–50% of the voting rights or has significant influence over their activities although it does not have authority to control those activities.

Unrealized gains/losses arising from the transactions between the Group and the Affiliate were corrected to the extent of the Group's share in the Affiliate. In the case that the book value of the investment in the Affiliate is zero or the Group's significant influence has ceased, the use of the equity method was discontinued as long as the Group has not entered into an obligation or made a commitment concerning the Affiliate. The book value of the investment as of the date when the significant influence has ceased is indicated at fair value if the fair value can be measured reliably following that date.

The interests in the affiliate as of March 31, 2021 and December 31, 2020 are shown below.

Affiliates	Shareholding Percentages (%)	
	March 31, 2021	December 31, 2020
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş. ("Sasbaş")	17	17

The financial details of Sasbaş are obtained from the statutory records of the affiliate pursuant to B15 (b) of TFRS 12 Disclosure of Interests in Other Entities.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.2 New and Revised Standards and Interpretations

a) New standards applicable as of March 31, 2021 and amendments and interpretations to the previous standards:

Definition of a Business (Amendments to TFRS 3)

The Public Oversight Authority (POA) issued amendments to the definition of a business in TFRS 3 "Business Combinations" in May 2019. The amendments are intended to assist entities to determine whether a transaction should be recognized as a business combination or as an asset acquisition.

The amendments:

- clarify the minimum requirements for a business;
- remove the assessment of whether market participants are capable of replacing any missing elements;
- add guidance to help entities assess whether an acquired process is substantive;
- narrow the definitions of a business and of outputs; and
- introduce an optional fair value concentration test.

Definition of Material (Amendments to TAS 1 and TAS 8)

In June 2019, the POA issued amendments to the standards "TAS 1 Presentation of Financial Statements" and "TAS 8 Accounting Policies, Changes in Accounting Estimates and Errors". These amendments are intended to align the definition of "material" used in the standards and to clarify certain parts of the definition. According to the new definition, information is material if omitting, misstating or obscuring could be expected to influence the decisions of primary users of general purpose financial statements make on the basis of those financial statements. The amendments make it clear that the materiality of information depends on its quality, magnitude or both. Companies are required to assess the materiality of the effect of information on financial statements when used alone or in combination with other information.

Amendments to TFRS 9, TAS 39 and TFRS 7 - Interest Rate Benchmark Reform

The amendments provide certain practical expedients related to the interest rate benchmark reform. The practical expedients concern hedge accounting, and the effect of the IBOR reform should not usually result in the termination of hedge accounting. Nevertheless, any hedging inefficiency must still be recognized in the income statement. Such practical expedients will affect all companies in the industry, given that hedge accounting is common in IBOR-based contracts.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.2 New and Revised Standards and Interpretations (Continued)

b) Standards and amendments issued but not yet in effect as of March 31, 2021

COVID-19-Related Rent Concessions (Amendments to TFRS 16)

As of March 2021, this amendment is extended to June 2022 and is in effect as from April 1, 2021. Certain rent concessions have been granted to lessees due to the COVID-19 outbreak. These concessions include suspension and deferral of rent payments to a later period. With an amendment to IFRS 16 Leases on May 28, 2020, IASB introduced an optional practical expedient allowing lessees not to assess whether particular rent concessions occurring as a direct consequence of the COVID-19 pandemic are lease modifications. Lessees may choose to recognize the rent concessions in accordance with the applicable provisions in the absence of lease modifications. This practical expedient often leads to the recognition of rent concessions as a variable rental payment in periods when an event or condition triggering the reduced payment occurs.

TFRS 17 – New Insurance Contracts Standard

The POA issued TFRS 17 in February 2019 as a new and comprehensive accounting standard related to recognition, measurement, presentation and disclosure of insurance contracts. TFRS 17 introduces a model that allows both the measurement of the liabilities arising from insurance contracts with the current balance sheet values and the recognition of profits throughout the period during which services are provided. TFRS 17 will be implemented for annual accounting periods beginning on or after January 1, 2023. Earlier implementation is permitted.

Classification of Liabilities as Short-term or Long-term (Amendments to TAS 1)

The POA amended the TAS 1 “Presentation of Financial Statements” on March 12, 2020. These amendments, which are intended to be applicable in the annual reporting periods starting on or after January 1, 2022, clarify the criteria related to the classification of liabilities as short-term and long-term. The amendments must be implemented retrospectively under the TAS 8 “Accounting Policies, Changes in Accounting Estimates and Errors”. Earlier implementation is permitted.

Amendment concerning references to the conceptual framework (Amendments to TFRS 3)

POA amended the TFRS Business Combinations standard in July 2020. The amendment was made to replace the reference to the former version of Conceptual Framework (1989 framework) with the reference to the current version issued in March 2018 (Conceptual Framework) without any significant change to the requirements under TFRS 3. However, a new paragraph was added to the TFRS 3 so as to define contingent assets failing to meet the criterion of recognition at the date of acquisition. The amendment will be implemented prospectively for the annual accounting periods beginning on or after January 1, 2022. If a company implements the amendments concerning the references to the Conceptual Framework (March 2018) in the TFRS standards at the same time or at an earlier date, earlier implementation is allowed.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.2 New and Revised Standards and Interpretations (Continued)

b) Standards and amendments issued but not yet in effect as of March 31, 2021 (Continued)

Proceeds before intended use (Amendments to TAS 16)

POA amended TAS 16 Property, Plant and Equipment in July 2020. The amendment requires companies to make an item of the property, plant and equipment consistent with its intended use and does not allow the deduction of proceeds from the sale of produced goods from the cost of the item. Companies will now recognize these proceeds from sales and associated costs in the profit or loss. The amendment will be implemented for annual periods beginning on or after January 1, 2022. The amendments could only be retrospectively implemented for the property, plant and equipment items introduced at the beginning of the earliest period or thereafter, which is presented comparatively with the accounting period when the company implemented the amendments for the first time. No exemption is granted to those that will implement the TFRS for the first time.

Onerous Contracts—Cost of Fulfilling a Contract (Amendments to TAS 37)

POA amended TAS 37 Provisions, Contingent Liabilities and Contingent Assets in July 2020. The amendment to TAS 37, which will be implemented for the accounting periods starting on January 1, 2022 and thereafter, was made to determine the costs to be taken into consideration when assessing whether it is an "onerous" or "loss-making" contract and involves the implementation of the "directly associated costs" approach. The amendments should be retrospectively implemented for the contracts under which the enterprise fails to fulfill all obligations, at the beginning of the annual reporting period (initial implementation date) when the amendments will be implemented for the first time. Earlier implementation is permitted.

Annual Improvements - 2018-2020 Period

"Annual Improvements related to the TFRS standards/2018-2020" were issued by POA in July 2020 and contain the following amendments:

- *TFRS 1 First-time Adoption of International Financial Reporting Standards – First Implementing Affiliate* The amendment allows a subsidiary to measure the accumulated foreign currency conversion adjustments using the amounts reported by the parent company. The amendment will also apply to affiliates and joint ventures.
- *TFRS 9 Financial Instruments - Fees in the '10 per cent' Test for Derecognition of Financial Liabilities* The amendment clarifies the fees taken into consideration by the enterprise in assessing whether or not there is material difference between the new or revised financial liability terms and original financial liability terms. These fees, including those paid by the parties on behalf of each other, involve only the fees paid between the debtor and the lender.
- *TAS 41 Agricultural Activities - Taxation in fair value measurements:* The amendment removed the provision on disregarding the cash flows made for the taxation related to the measurement of the fair value of assets of the companies under TAS 41 as set forth in paragraph 22 of TAS 41.

All improvements will apply to annual accounting periods beginning on or after January 1, 2022. Earlier implementation is permitted.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.2 New and Revised Standards and Interpretations (Continued)

b) Standards and amendments issued but not yet in effect as of March 31, 2021 (Continued)

Narrow-scope amendments to TAS 1, Practice Statement 2 and TAS 8

They are effective from annual reporting periods beginning on or after January 1, 2023. These amendments are intended to improve accounting policy disclosures and to help users of financial statements distinguish between changes in accounting estimates and changes in accounting policies.

Interest Rate Benchmark Reform - Phase 2 (Amendments to TFRS 9, TMS 39, TFRS 7, TFRS 4 and TFRS 16)

In December 2020, POA issued Interest Rate Benchmark Reform - Phase 2 - Amendments to TFRS 9, TMS 39, TFRS 7, TFRS 4 and TFRS 16, which provide temporary reliefs to eliminate the effects of the replacement of the Interbank Offering Rate (IBOR) with an alternative reference interest rate on financial reporting. Companies will implement these amendments in the annual accounting period starting on or after January 1, 2021. Earlier implementation is permitted.

Amendments to TFRS 17 and TFRS 4 Insurance Contracts and deferral of the implementation of TFRS 9

They are effective from annual reporting periods beginning on or after January 1, 2023. These amendments defer the date of the temporary exemption under TFRS 4 concerning implementation of TFRS 9 Financial Instruments to January 1, 2023.

2.3 Changes in Accounting Policies

The changes to accounting policies brought by the first application of a new TFRS are applied in accordance with the transitional provisions of the TFRS. In the event of no transitional provisions being included in the TFRS, or an optional material change being made to accounting policy, they are applied retrospectively, and the consolidated financial statements of the previous period are revised.

2.4 Comparative Information and Revision of Financial Statements for the Previous Period

The attached consolidated financial statements for the interim period are prepared comparatively to the prior period to allow the assessment of the Group's consolidated financial position, performance and cash flow trends. To ensure comparability when the demonstration or classification of the items in the consolidated financial statements for the interim period, the consolidated financial statements of the previous period are reclassified accordingly and explanations are provided regarding these issues.

The "right-of-use" assets amounting to 2,395,579 TRY classified under Property, Plant and Equipment in the consolidated statement of financial position of the Group as of December 31, 2020 were reclassified in the current period and presented as an "individual" item of financial statements in the consolidated statements of financial position dated March 31, 2021 and December 31, 2020.

2.5 Changes in Accounting Estimates and Errors

The effects of the changes in an accounting estimate are reflected in the financial statements in the current period in which the change is made, and reflected both in the current and future periods prospectively if they also concern the future periods so that they are taken into account when calculating the net profit and loss for the period.

The corrected amount of an error is taken into account retrospectively. In the event of an error prior to the rearrangement of the comparative amounts associated with the previous periods in which the error occurred, or before the next reporting period, the error is corrected by rearranging the accumulated profit account for the respective period. Should the rearrangement of the information result in excessive cost, the comparative information of the previous periods will not be rearranged, and the accumulated profit account for the next period will be rearranged with the cumulative effect of the error before the beginning of the said period.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.6 Summary of Significant Accounting Policies

Revenue

Revenues are recognized on an accrual basis at the time when deliveries are made, the amount of revenue can be measured reliably and it is probable that the economic benefits associated with the transaction will flow to the Group at the fair value of considerations that is or can be received. Net sales represent the sale price of goods sold net of the price of returned goods, discounts, commissions and related taxes. The Group recognizes the revenues based on the following conditions:

- (a) identification of customer contracts,
- (b) identification of performance liabilities,
- (c) determination of transaction price in the contract,
- (d) sorting of the prices related to the performance liabilities,
- (e) recognition of revenue when the performance liabilities are fulfilled.

The Group solely records the revenues earned from the customers when the conditions mentioned below are met:

- (a) If the contracting parties have approved the contract (in writing, verbally or by other usual business practices) and undertaken to fulfill the individual liabilities specified in the contract,
- (b) If the Group can define its rights and liabilities of both parties in relation to the product or service,
- (c) If the Company can stipulate terms of payment for the products and services,
- (d) If the contract has the characteristics of a business transaction,
- (e) The Group is likely to collect the prices of the goods and services provided to the customers.
- (f) The Company should take into account only the solvency and willingness-to-pay of the customer on the due date when assessing the collectability of the mentioned fee.

The Group's revenues arise from sale of wheat, corn, flour, bran, rasmol and ear.

Investment Properties

Lands or buildings or parts thereof held (by the owner or by the lessee depending on the financial lease contract) to obtain rental income or appreciation gains or both instead of being used for production or procurement of goods and services or for administrative purposes or being sold in the ordinary course of business are classified as investment properties.

An investment property is recognized as an asset in the case that the future economic benefits associated with it are likely to flow to the company and its cost can be reliably measured. Investment properties are reflected in the consolidated financial statements based on their revalued amount. Appreciation gains or impairment losses based on valuation reports are recognized in profit or loss in the period in which they arise.

Investment properties are reviewed to determine a potential impairment, and the book value of an investment property is reduced to the recoverable value by setting aside a provision in the event of the book value exceeding its recoverable value.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.6 Summary of Significant Accounting Policies (Continued)

Property, Plant and Equipment

The Group's property, plant and equipment, such as its underground and ground plants and fixtures, are shown as cost values, including the costs incurred to make them available for use, net of accumulated depreciation and accumulated impairment. Lands, buildings, machinery, facilities, equipment and vehicles are included in the consolidated financial statements based on the revaluation model and the value differences are reported among the equities under the revaluation reserve and in the comprehensive income statement for the relevant period. In the case that an item of property, plant and equipment is sold, the cost and accumulated depreciation of this item is removed from the relevant accounts and the arising profit or loss is recognized in the profit or loss statement. Assets other than plots of land are subjected to depreciation based on the rate of depreciation designated according to the asset's useful life.

The expenses arising from the replacement of any part of the property, plant and equipment can be capitalized along with the maintenance and repair costs if they increase the future economic benefit of the asset. All other expenses are recognized as expense items in the income statement. In case of conditions suggesting an impairment in an item of property, plant and equipment, a review is carried out and the book value of the item is reduced to the recoverable value by setting aside a provision if its book value exceeds its recoverable value.

If the book value of the item of property, plant and equipment increases as a result of revaluation, this increase is directly included in the consolidated financial statement under the name "revaluation reserve" in the equity account group. However, any increase in value as a result of revaluation is recognized as revenue in consolidated financial statements to the extent that the same asset reverses the revaluation impairment previously recognized as an expense. If the book value of the asset decreases as a result of the revaluation, this impairment is recognized as an expense in the financial statements. However, if a revaluation reserve has been established regarding the asset, the impairment is first removed from that account. In the event that the impairment exceeds the revaluation reserve, the exceeding part is associated with the income statement.

The estimated economic lives of property, plant and equipment are as follows:

Type of Asset	Estimated Economic Life
Underground and Ground Plants	25–50 years
Buildings	25–50 years
Facilities, Machinery and Equipment	4–50 years
Vehicles	2–15 years
Fixtures	3–50 years

Depreciation methods, useful lives and residual values are reviewed as of each reporting date and adjusted when necessary.

Intangible Assets

Intangible assets are recognized based on their acquisition cost and subjected to depreciation based on the rate of depreciation designated according to their useful life.

Type of Intangible Asset	Estimated Economic Life
Rights	3–15 years

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.6 Summary of Significant Accounting Policies (Continued)

Impairment of assets

For financial assets that are not recognized in profit or loss, an assessment is made, at the end of each reporting period, as to whether there is any objective evidence that they are impaired.

Objective evidence of impairment of financial assets includes:

- significant financial difficulty of the issuer or obligor;
- the lender granting to the Group a concession that the lender would not otherwise consider;
- it becoming probable that the borrower or issuer will enter bankruptcy;
- a default or delinquency of these persons;
- the disappearance of an active market for a financial asset or
- observable data indicating that there is a measurable decrease in the estimated future cash flows from the financial asset.

The fair value of an investment based on equity shares dropping significantly or permanently below its cost value is also objective evidence of impairment.

Borrowing costs

In case of assets for which it takes considerable time to make them available for use and sale, the borrowing costs that can be directly associated with the purchase, construction or production of the asset are capitalized as an item of its cost until the asset is made available for use or sale. The borrowing costs that do not fall into this scope are recognized as expense in the period in which they are incurred. The Group recognizes all financing expenses in profit or loss in the period in which they are incurred.

Inventories

Inventories are valued with their net realizable value or cost, depending on which is lower. The cost of inventories consists of all acquisition costs and other costs incurred to bring them to their existing state and position. Net realizable value is the amount obtained by deducting the estimated completion cost and the estimated sale cost required to carry out the sale from the estimated sale price formed during the ordinary course of business. Weighted average cost method is employed as the inventory valuation method.

Financial Assets

Cash and Cash Equivalents

Cash and cash equivalent items include cash, demand deposits, term deposits (with a maturity less than three months) and other highly liquid short-term investments that are due in three months or less from the date of purchase, can be converted into cash immediately and have no risk of considerable change in value. The Group reviews its cash and cash equivalents for impairment using the expected credit loss model.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.6 Summary of Significant Accounting Policies (Continued)

Financial Assets (Continued)

Trade and Other Receivables

Trade and other receivables are recognized at fair value initially. In the reporting periods following the initial recognition, they are measured at amortized cost using the effective interest method. If it is found that a trade receivable will not be able to be collected, it is recognized in profit or loss by setting aside a provision for the uncollectible part of the receivable. The Group reviews its trade receivables for impairment using the expected credit loss model.

Derivative Instruments

Derivative instruments are initially recognized at their acquisition cost reflecting their fair value and measured at fair value in the periods following their initial recognition. While they provide effective economic protection against risks for the Company, they are recognized as derivative instruments for trade purposes in cases where they do not meet the necessary conditions from the perspective of hedge accounting and changes in their fair value are recognized in income statement.

Financial Liabilities

Financial Payables

Interest-bearing financial payables are initially recognized at fair value and subsequently measured using the effective interest rate method.

Trade and Other Payables

Trade and other payables are initially recognized at fair value and subsequently measured at amortized value using the effective interest rate method.

Effects of changes in exchange rates

The transactions recognized in foreign currencies (currencies other than TRY) in the statutory records of the Group are converted into Turkish lira based on the exchange rates on the date of the transactions. Assets and liabilities in foreign currency in the consolidated statement of financial position are converted into Turkish lira based on the exchange rates on the reporting date. Foreign currency gains and losses arising from this conversion and the collection and payment of transactions in foreign currencies are recognized in consolidated profit or loss statement.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.6 Summary of Significant Accounting Policies (Continued)

Earnings (Loss) per Share

Earnings/loss per share is calculated by dividing the net profit or loss for the period by the weighted average number of ordinary shares of the ordinary equity holders in the current period.

The companies in Turkey can increase their capital by distributing shares (bonus share) to their existing shareholders in proportion to their shareholding rate from retained earnings and equity inflation adjustment differences. These bonus shares are considered preference shares when calculating the profit/loss per share. Therefore, the weighted equity share average used in the calculation of profit/loss per share is obtained by retrospectively applying it for bonus shares.

Events after the reporting period

This refers to events, whether positive and negative for the company, which occur between the end of the reporting period and the date authorization is given for the publication of the consolidated statement of financial position. The two types of events after the reporting period are:

- New evidence related to events being present as of the end of the reporting period (events that require adjustment after the reporting period) and
- Evidence indicating that the events occurred after the reporting period (events that do not require adjustment after the reporting period).

If new evidence emerges that the events were present at the end of the reporting period, or that they occurred after the reporting period and thus require adjustment of consolidated financial statements, the Group adjusts them in accordance with the new situation. If the events do not require the financial statements to be adjusted, the Group provides explanations for these matters.

Related parties

The Group's shareholders, the companies owned by them, their managers and other persons and entities that are known to be related to them are defined as related parties in the attached consolidated financial statements. Related party refers to direct or indirect control of the Group, a right to have significant influence over the Group, or an affiliate, board member and general manager of the Group.

Taxation

Income tax expenses consist of the current tax and total deferred tax.

(i) Current tax

Current tax is the expected tax liability or tax claim over profit or loss that is subject to taxation within the current year, and includes the tax liability and related adjustment records from the previous years.

It is calculated based on the tax rates that are applicable or will almost definitely be in effect as of the end of the reporting period. Current tax assets and liabilities can be offset only when certain conditions are met.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.6 Summary of Significant Accounting Policies (Continued)

Taxation (Continued)

(ii) Deferred tax

Deferred tax is calculated using the liability method, based on the temporary differences between the recognized values of assets and liabilities in the consolidated financial statements and their tax values.

Deferred tax liabilities are calculated for all taxable temporary differences, whereas deferred tax assets resulting from deductible temporary differences are calculated on condition that the utilization of these differences to earn taxable profits in the future is highly likely.

Employee benefits

(i) Short-term employee benefits

Short-term employee benefits are recognized as expense as services are provided. A liability is recognized for amounts arising from the Group's legal or implied acceptance of the previous services of its employees, which the Company is liable to pay and are expected to be paid in cases where this liability can be estimated reliably.

(ii) Other long-term employee benefits

Severance pay provisions are based on the present value of the estimated potential future liabilities for a period of 30 days in the event of the retirement of the Group's employees. Severance pay provisions are calculated as if all employees will receive such payments, and recognized in financial statements on an accrual basis. Severance pay provisions are calculated in accordance with the severance pay cap announced by the government.

As of March 31, 2021, the exact amount of the severance pay cap is 7,638.96 TRY (December 31, 2020: 7,117.17 TRY) The Group management used some estimates for the calculation of severance pay provisions.

All actuarial gains and losses related to severance pay provisions are recognized in other comprehensive income.

Contingent Assets and Liabilities

According to TAS 37 "Provisions, Contingent Liabilities and Contingent Assets", the Group must have an existing statutory or implied liability arising from previous events, the outflow of resources involving economic benefits must be probable and the said liability must be able to be estimated in a reliable manner so that any provision amount can be included in the financial statements. In the event of such criteria not being met, the Group explains such issues in the relevant footnotes.

If the inflow of economic benefit becomes probable, explanations regarding the contingent asset are provided in the footnotes to the consolidated financial statements. If the inflow of economic benefit becomes definite, the asset and the associated income are recognized in the consolidated financial statements on the date of the change.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
(Continued)**

2.6 Summary of Significant Accounting Policies (Continued)

Leases

Determining whether a contract has any leasing element

At the beginning of a contract, the Group determines whether it is a lease contract or a contract that includes leasing elements. At the beginning of the contract or following its reevaluation, the Group divides the payments required under the contract as payments for leasing and other purposes, based on their relative fair values.

If the Group decides that it is not possible to reliably divide the payments under a financial leasing contract, an asset and a liability equivalent to the asset are recognized. The liability is reduced as the payments are completed, and the financing costs added to the liability are recognized using the Group's incremental borrowing rate of interest.

Leased assets

Assets that are used by way of leasing in which all material risks and returns relating to the ownership of the asset are transferred to the Group are classified as financial leases. Fixed assets acquired through financial leasing are initially recognized at fair value or present value the minimum financial lease payments, depending on which is lower. Following their initial recognition, they are recognized according to the accounting policies applicable to them.

Lease payments

The minimum lease payments under a financial lease contract are apportioned as financial expenses and reduction of the remaining liability. Financing expenses are distributed among each period constituting the term of the lease using a fixed period interest rate over the remaining balance of the liability.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 3 - REPORTING BY SEGMENTS**

The information grouped under reportable segments as of March 31, 2021 and March 31, 2020 are as follows:

March 31, 2021	Wheat and Flour Trade	Licensed Warehousing Services	Elimination	Total
Sales	1,577,329,267	2,484,502	(103,976,925)	1,475,836,844
Cost of Sales	(1,512,133,183)	(1,532,336)	111,096,445	(1,402,569,074)
Gross Operating Profit	65,196,084	952,166	7,119,520	73,267,770
Research and Development Expenses	(13,116)	-	-	(13,116)
Overhead Expenses (-)	(8,781,005)	(547,263)	197,305	(9,130,963)
Marketing, Sale and Distribution Expenses (-)	(24,954,533)	-	8,241	(24,946,292)
Other Operating Income	75,485,547	307,618	(310,022)	75,483,143
Other Operating Expenses (-)	(34,747,449)	(120,018)	-	(34,867,467)
Operating Profit/Loss	72,185,528	592,503	7,015,044	79,793,075
Income from Investing Activities	283,538	-	-	283,538
Cancelled Impairment Earnings and Losses Determined as per TFRS 9	(266,588)	-	-	(266,588)
Shares from Profits (Losses) of Investments Valued by Equity Method	172,727	-	-	172,727
Operating Profit/Loss Before Finance Expense	72,375,205	592,503	7,015,044	79,982,752
Finance Income	86,820,216	908,419	(2,039,652)	85,688,983
Finance Expenses (-)	(143,556,947)	(1,871,915)	(4,975,392)	(150,404,254)
Profit Before Tax	15,638,474	(370,993)	-	15,267,481
Tax Expense	(3,190,767)	(614,880)	-	(3,805,647)
Net Profit/Loss for the Period	12,447,707	(985,873)	-	11,461,834

March 31, 2020	Wheat and Flour Trade	Licensed Warehousing Services	Elimination	Total
Sales	1,119,107,892	2,118,221	(62,118,817)	1,059,107,296
Cost of Sales	(1,058,150,026)	(553,470)	61,417,420	(997,286,076)
Gross Operating Profit	60,957,866	1,564,751	(701,397)	61,821,220
Research and Development Expenses	(45,073)	-	-	(45,073)
Overhead Expenses (-)	(4,935,640)	(303,701)	200,313	(5,039,028)
Marketing, Sale and Distribution Expenses (-)	(13,863,968)	-	806,915	(13,057,053)
Other Operating Income	48,628,095	474,502	(307,713)	48,794,884
Other Operating Expenses (-)	(15,393,031)	(55,184)	1,882	(15,446,333)
Operating Profit/Loss	75,348,249	1,680,368	-	77,028,617
Income from Investing Activities	390,103	-	-	390,103
Cancelled Impairment Earnings and Losses Determined as per TFRS 9	(196,760)	-	-	(196,760)
Shares from Profits (Losses) of Investments Valued by Equity Method	227,214	-	-	227,214
Operating Profit/Loss Before Finance Expense	75,768,806	1,680,368	-	77,449,174
Finance Income	46,253,730	719	(432,673)	45,821,776
Finance Expenses (-)	(97,486,836)	(197,666)	432,673	(97,251,829)
Profit Before Tax	24,535,700	1,483,421	-	26,019,121
Tax Expense	(6,640,737)	54,396	-	(6,586,341)
Net Profit/Loss for the Period	17,894,963	1,537,817	-	19,432,780

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 3 - REPORTING BY SEGMENTS (Continued)**

March 31, 2021	Wheat and Flour Trade	Licensed Warehousing Services	Elimination	Total
Total Assets	2,383,080,550	85,359,751	(170,948,776)	2,297,491,525
Total Liabilities	1,966,960,056	41,379,462	(116,088,724)	1,892,250,794
Parent Company Equity	416,120,494	43,980,289	(54,860,052)	405,240,731
Non-Controlling Interests	-	-	-	-

March 31, 2020	Wheat and Flour Trade	Licensed Warehousing Services	Elimination	Total
Total Assets	1,705,240,392	24,165,024	(89,167,915)	1,640,237,501
Total Liabilities	1,360,391,222	11,301,045	(63,520,603)	1,308,171,664
Parent Company Equity	344,849,170	12,863,979	(25,647,312)	332,065,837
Non-Controlling Interests	-	-	-	-

March 31, 2021	Wheat and Flour Trade	Licensed Warehousing Services	Total
Investment Expenditures	12,486,975	936,709	13,423,684
Depreciation Expense for the Period	5,776,272	579,567	6,355,839

March 31, 2020	Wheat and Flour Trade	Licensed Warehousing Services	Total
Investment Expenditures	2,373,487	1,498,323	3,871,810
Depreciation Expense for the Period	2,229,787	103,638	2,333,425

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 4 - CASH AND CASH EQUIVALENTS**

Details of the cash and cash equivalents as of March 31, 2021 and December 31, 2020 are as follows:

Cash and Cash Equivalents	March 31, 2021	December 31, 2020
Cash	46,758	63,954
Demand Deposits	153,515,438	109,332,781
Time Deposits	282,849,905	199,760,780
POS Accounts	298,765	238,675
Fund Accounts	20,651,022	18,613,878
Expected Credit Loss	(282,450)	(164,886)
	457,079,438	327,845,182

USD and TRY Time Deposit Interest Rate Ranges as of March 31, 2021 are 0.75%–3.0% and 17–19%, respectively. (December 31, 2020: USD Time Deposit: 1.75–3.5%; TRY Time Deposit: 15–17.75%)

Bank deposits as of March 31, 2021 are as follows:

	March 31, 2021
Banks	436,365,343
Demand Deposits	153,515,438
- TRY Bank	6,443,368
- EUR Bank	11,894,846
- USD Bank	126,467,933
- GBP Bank	116,963
- CHF Bank	8,592,328
Time Deposits	282,849,905
- TRY Time Deposits	87,713,828
- USD Time Deposits	195,136,077
	436,365,343

FOOTNOTE 5 - FINANCIAL INVESTMENTS

Details of the financial investments as of March 31, 2021 and December 31, 2020 are as follows:

Short-term Financial Investments	March 31, 2021	December 31, 2020
Bonds	54,845,069	29,712,658
Blocked Bank Accounts	10,489,761	2,392,122
	65,334,830	32,104,780

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 6 – FINANCIAL BORROWING**

Short-term borrowings as of March 31, 2021 and December 31, 2020 are as follows:

Short-term Financial Borrowings	March 31, 2021	December 31, 2020
Short-term Borrowings	640,742,553	340,126,709
- Bank Loans	640,677,295	340,126,709
- Credit Cards	65,258	-
	640,742,553	340,126,709

Bank loans as of March 31, 2021 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD		34,229,773	285,503,695
TRY	2.00–20%		340,466,764
EUR	4.00%	1,502,783	14,706,836
			640,677,295

Short-term borrowings as of December 31, 2020 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	0,29–1.84%	15,737,218	115,519,049
TRY	7.44–16.20%		224,607,660
			340,126,709

Short-term portions of long-term borrowings as of March 31, 2021 and December 31, 2020 are as follows:

Short-term Portions of Long-term Borrowings	March 31, 2021	December 31, 2020
Principal Instalments of Long-term Loans	203,739,935	181,930,423
Leasing Payables	6,046,753	4,064,565
Finance Lease Cost of Borrowing Account (-)	(418,170)	-
	209,368,518	185,994,988

Short-term portions of long-term borrowings as of March 31, 2021 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	0,29–6.00%	5,916,263	49,346,367
TRY	8.00–19.00%		154,393,568
			203,739,935

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 6 – FINANCIAL BORROWING (Continued)**

Short-term portions of long-term borrowings as of December 31, 2020 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	0.29–7.43%	4,509,980	33,105,506
EUR	3–4%	2,256,317	20,324,676
TRY	7.5–16.5%		128,500,241
			181,930,423

Payables related to short-term leases as of March 31, 2021 are as follows:

Currency	Amount in Foreign Currency	Amount in TRY
USD	555,493	4,633,256
EUR		-
TRY		995,327
		5,628,583

Payables related to short-term leases as of December 31, 2020 are as follows:

Currency	Amount in Foreign Currency	Amount in TRY
USD	445,171	3,267,776
EUR		-
TRY		796,789
		4,064,565

Long-term borrowings as of March 31, 2021 and December 31, 2020 are as follows:

Long-term Borrowings	March 31, 2021	December 31, 2020
Long-term Bank Loans	257,462,755	286,395,403
Leasing Payables	5,040,263	6,762,513
Finance Lease Cost of Borrowing (-)	(135,014)	-
	262,368,004	293,157,916

Long-term borrowings as of March 31, 2021 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	0.29–6.00%	11,982,194	99,941,084
EUR			-
TRY	8.00–19.00%		157,521,671
			257,462,755

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 6 – FINANCIAL BORROWING (Continued)**

Long-term borrowings as of December 31, 2020 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	0.29–7.43%	16,348,967	120,009,591
EUR	3–4%	-	-
TRY	7.5–16.5%	-	166,385,812
			286,395,403

Payables related to long-term leases as of March 31, 2021 are as follows:

Currency	Amount in Foreign Currency	Amount in TRY
USD	612,416	4,495,627
EUR	-	-
TRY	-	409,622
		4,905,249

Payables related to long-term leases as of December 31, 2020 are as follows:

Currency	Amount in Foreign Currency	Amount in TRY
USD	786,396	5,772,539
EUR	-	-
TRY	-	989,974
		6,762,513

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 7 – TRADE RECEIVABLES AND PAYABLES**

Short-term trade receivables as of March 31, 2021 and December 31, 2020 are as follows:

Short-term Trade Receivables	March 31, 2021	December 31, 2020
Trade Receivables from Related Parties	873,554	904,662
Trade Receivables from Unrelated Parties	755,716,073	403,520,504
Notes Receivable from Related Parties	603,280	480,049
Notes Receivable from Unrelated Parties	50,323,314	28,260,053
Deferred Due Date Difference Income (-)	(2,088,178)	(2,659,451)
Bad Debt	7,340,638	7,521,114
Provision for Bad Debt (-)	(7,340,638)	(7,521,114)
	805,428,043	430,505,817

Bad debt activity as of March 31, 2021 and December 31, 2020 is as follows:

Bad Debt	March 31, 2021	December 31, 2020
Bad Debt at the Beginning of the Period	7,521,114	7,588,747
Provision Set Aside within the Period	-	520,408
Taken over by GK Tarım	-	10,613
Canceled Provisions (-)	(180,476)	(598,654)
	7,340,638	7,521,114

Long-term trade receivables as of March 31, 2021 and December 31, 2020 are as follows:

Long-term Trade Receivables	March 31, 2021	December 31, 2020
Trade Receivables from Related Parties	-	-
Trade Receivables from Unrelated Parties (*)	10,197,097	10,197,097
	10,197,097	10,197,097

(*) See Footnote 18.

Short-term trade payables as of March 31, 2021 and December 31, 2020 are as follows:

Short-term Trade Payables	March 31, 2021	December 31, 2020
Trade Payables to Related Parties	5,437,067	89,877
Trade Payables to Unrelated Parties (*)	659,968,344	394,667,095
Notes Payable to Related Parties	-	-
Notes Payable to Unrelated Parties	1,130,311	-
Deferred Due Date Difference Expense (-)	(4,021,288)	(2,751,349)
	662,514,434	392,005,623

(*) 424,993,096 TRY of trade payables to unrelated parties as of March 31, 2021 is letter of credit payables. (December 31, 2020: 345,032,008 TRY)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 8 – OTHER RECEIVABLES AND PAYABLES**

Other short-term receivables from unrelated parties as of March 31, 2021 and December 31, 2020 are as follows:

Other Short-term Receivables	March 31, 2021	December 31, 2020
Deposits and Guarantees Given	664,654	564,318
Other Receivables from Unrelated Parties	624,372	917,753
Receivables from Public Bodies	8,223,393	13,661,989
	9,512,419	15.144.060

Other long-term receivables from unrelated parties as of March 31, 2021 and December 31, 2020 are as follows:

Other Long-term Receivables	March 31, 2021	December 31, 2020
Deposits and Guarantees Given	284,414	285,615
	284,414	285,615

Other short-term payables as of March 31, 2021 and December 31, 2020 are as follows:

Other Short-term Payables	March 31, 2021	December 31, 2020
Other Payables to Unrelated Parties	486,792	519,359
Other Payables to Related Parties	14,592,129	14,959,964
	15,078,921	15,479,323

FOOTNOTE 9 – DERIVATIVE INSTRUMENTS

Derivative financial assets as of March 31, 2021 and December 31, 2020 are as follows:

Derivative Financial Assets	March 31, 2021	December 31, 2020
Derivatives Market Collaterals	47,452,721	7,426,028
Derivative Financial Instruments	8,931,233	3,242,525
	56,383,954	10,668,553

Derivative financial liabilities as of March 31, 2021 and December 31, 2020 are as follows:

Derivative Financial Liabilities	March 31, 2021	December 31, 2020
Derivative Financial Instruments	15,157,538	2,017,984
	15,157,538	2,017,984

(*) Collaterals given to carry out transactions in the derivatives market are classified as derivatives market collaterals, and fair values of forward contracts and option contracts are classified as derivative financial instruments. Profits or losses arising from the transactions carried out during the period are reported as derivative financial instrument income and expenses in finance income and expenses in the profit or loss statement, and the fair value differences of open positions as of the reporting date are reported as finance income and expenses.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 9 – DERIVATIVE INSTRUMENTS (Continued)****Fair Value of Financial Instruments**

Based on the source of valuation inputs of each financial instrument class, the Group categorizes the financial instruments recognized at fair value according to the three-level hierarchy.

Level 1: Valuation techniques using quoted prices in active markets for identical assets or liabilities that the Group has the ability to access at the measurement date;

Level 2: Other valuation techniques involving inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly;

Level 3: Valuation techniques using unobservable inputs for the assets or liability.

March 31, 2021	Level 1	Level 2	Level 3
Forward Exchange Contracts (for Trade Purposes)	-	41,226,416	-
	-	41,226,416	-
December 31, 2020	Level 1	Level 2	Level 3
Forward Exchange Contracts (for Trade Purposes)	-	8,650,569	-
	-	8,650,569	-

Forward exchange transactions (Level 2) are valued using foreign exchange rates on the date of the balance sheet and discounting the fair value of the forward exchange contract to the present day.

FOOTNOTE 10 – INVENTORIES

Inventories as of March 31, 2021 and December 31, 2020 are as follows:

Inventories	March 31, 2021	December 31, 2020
Raw Materials and Supplies	117,476,589	139,309,235
Finished Goods	37,688,558	6,470,765
Goods in Transit	-	3,083,530
Merchandise	227,273,375	309,705,504
Other Inventories	764,444	668,518
Provision for Inventory Impairment (-)	(123,509)	(123,727)
	383,079,457	459,113,825

There is no lien, claim or pledge on the inventories, which are insured.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 11 - PREPAID EXPENSES AND DEFERRED INCOME**

Short-term prepaid expenses as of March 31, 2021 and December 31, 2020 are as follows:

Short-term Prepaid Expenses	March 31, 2021	December 31, 2020
Advance Payments for Orders Placed with Related Parties	-	415,012
Advance Payments for Orders Placed with Unrelated Parties	66,635,343	46,750,495
Insurance and Other Pre-paid Expenses	92,174,907	1,731,434
	158,810,250	48,896,941

Long-term prepaid expenses as of March 31, 2021 and December 31, 2020 are as follows:

Long-term Prepaid Expenses	March 31, 2021	December 31, 2020
Insurance Expenses	821,623	-
Advance Payments for Orders Placed with Unrelated Parties	-	3,042,014
	821,623	3,042,014

Short-term deferred income as of March 31, 2021 and December 31, 2020 is as follows:

Short-term Deferred Income	March 31, 2021	December 31, 2020
Advance Payments from Related Parties	-	-
Advance Payments from Unrelated Parties	33,404,212	20,813,623
Deferred Income	70,000	100,000
	33,474,212	20,913,623

FOOTNOTE 12 – INVESTMENTS VALUED BY EQUITY METHOD

Investments valued by equity method as of March 31, 2021 and December 31, 2020 are as follows:

Name of Affiliate	%	March 31, 2021	%	December 31, 2020
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	17	5,109,026	17	4,936,299
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.		January 1 - March 31, 2021		January 1 - December 31, 2020
As of January 1		4,936,299		4,612,490
Interest in Profits/Losses		172,727		867,151
Accrued Dividend Income		-		(543,342)
As of the End of the Period		5,109,026		4,936,299

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 12 – INVESTMENTS VALUED BY EQUITY METHOD (Continued)**

Condensed financial statements of the investment valued by equity method are as follows:

Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	March 31, 2021	December 31, 2020
Current Assets	7,273,798	4,844,084
Non-current Assets	10,312,287	11,425,865
Total Assets	17,586,085	16,269,949
Short-term Liabilities	3,139,152	677,535
Long-term Liabilities	4,350,740	6,512,261
Equities	10,096,193	9,080,153
Total Liabilities and Equity	17,586,085	16,269,949

	January 1 - March 31, 2021	January 1 - December 31, 2020
Sales Income	2,550,064	12,517,873
Net Profit/Loss for the Period	1,016,040	5,100,889

Interests in profits/losses of the investments valued by equity method as of the periods ended March 31, 2021 and March 31, 2020 are as follows:

	January 1 - March 31, 2021	January 1 - March 31, 2020
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	172,727	227,214
	172,727	227,214

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 13 – INVESTMENT PROPERTIES**

Investment properties as of March 31, 2021 and December 31, 2020 are as follows:

Description	January 1, 2021	Acquisitions	Disposals	Transfers	March 31, 2021
Plots of Land	8,283,231	-	-	-	8,283,231
Buildings	4,580,454	-	-	-	4,580,454
Total Cost	12,863,685	-	-	-	12,863,685

Description	January 1, 2020	Subsidiary Acquisition	Revaluation	Transfers	December 31, 2020
Lands and Plots	7,515,000	1,845	766,386	-	8,283,231
Buildings	3,985,000	157,840	437,614	-	4,580,454
Total Cost	11,500,000	159,685	1,204,000	-	12,863,685

Investment properties are reported at fair value. To determine the fair value, a valuation report was drawn up by Varlık Taşınmaz Değerleme ve Danışmanlık A.Ş. on February 15, 2021. Market approach, cost approach and income approach methods were employed in the valuation of the properties. The valuation report states that income approach was followed since properties earn income, but concludes that the result obtained from the cost method is more realistic on the grounds that there are not many facilities for rent of similar qualities in the region, which is not fully industrialized, and thus uses the value obtained by the cost method. Fair value of lands and buildings is valued at 12,704,000 TRY. Fair value differences of investment properties as of the reporting date are reported in the investment income/expenses account.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 14 – ASSETS RELATED TO CURRENT PERIOD TAX**

Assets relating to current tax as of March 31, 2021 and December 31, 2020 are as follows:

Assets Related To Current Period Tax	March 31, 2021	December 31, 2020
Prepaid Taxes and Funds	1,543,726	1,262,430
	1,543,726	1,262,430

FOOTNOTE 15 – RIGHT-OF-USE ASSETS

Right-of-use assets as of March 31, 2021 and December 31, 2020 are as follows:

Description	January 1, 2021	Acquisitions	Disposals	Transfers	March 31, 2021
Buildings	2,008,867	-	-	-	2,008,867
Vehicles	1,617,902	-	-	-	1,617,902
Total	3,626,769	-	-	-	3,626,769

Buildings	(388,331)	(152,118)	-	-	(540,449)
Vehicles	(842,859)	(203,589)	-	-	(1,046,448)
Accumulated Depreciation	(1,231,190)	(355,707)	-	-	(1,586,897)
Net Book Value	2,395,579				2,039,872

Description	January 1, 2020	Acquisitions	Disposals	Transfers	December 31, 2020
Buildings	-	2,008,867	-	-	2,008,867
Vehicles	-	1,617,902	-	-	1,617,902
Total	-	3,626,769	-	-	3,626,769

Buildings	-	(388,331)	-	-	(388,331)
Vehicles	-	(842,859)	-	-	(842,859)
Accumulated Depreciation	-	(1,231,190)	-	-	(1,231,190)
Net Book Value	-	2,395,579			2,395,579

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 16 – PROPERTY, PLANT AND EQUIPMENT**

Property, plant and equipment as of March 31, 2021 and December 31, 2020 are as follows:

Description	January 1, 2021	Acquisitions	Disposals	Transfers	Revaluation	March 31, 2021
Lands and Plots	23,141,629	44,344	-	-	-	23,185,973
Buildings	84,302,093	3,669,484	-	-	-	87,971,577
Underground and Ground Plants	4,530,713	80,803	-	-	-	4,611,516
Facilities, Machinery and Equipment	182,909,160	1,709,700	(17,735)	-	-	184,601,125
Vehicles	14,363,043	92,121	(138,367)	-	-	14,316,797
Fixtures	4,759,051	838,451	(38,568)	-	-	5,558,934
Special Costs	82,081	13,067	-	-	-	95,148
Ongoing Investments	3,259,198	6,620,502	-	-	-	9,879,700
Total Cost	317,346,968	13,068,472	(194,670)	-	-	330,220,770

Accumulated Depreciation	January 1, 2021	Expenses for the Period	Disposals	Transfers	Revaluation	March 31, 2021
Lands and Plots	-	-	-	-	-	-
Buildings	(6,035,873)	(550,728)	-	-	-	(6,586,601)
Underground and Ground Plants	(113,337)	(27,530)	-	-	-	(140,867)
Facilities, Machinery and Equipment	(21,018,077)	(2,854,546)	1,048	-	-	(23,871,575)
Vehicles	(3,410,955)	(2,212,629)	87,761	-	-	(5,535,823)
Fixtures	(1,158,416)	(248,078)	23,206	-	-	(1,383,288)
Special Costs	(12,579)	(4,443)	-	-	-	(17,022)
Ongoing Investments	-	-	-	-	-	-
Total	(31,749,237)	(5,897,954)	112,015	-	-	(37,535,176)
Property, Plant and Equipment (Net)	285,597,731					292,685,594

There is 41,400,000 USD bank mortgage on the fixed assets.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 16 – PROPERTY, PLANT AND EQUIPMENT (Continued)**

Description	January 1, 2020	Acquisitions	Disposals	Transfers	Revaluation and Reclassification	Subsidiary Acquisition	December 31, 2020
Lands and Plots	21,938,350	1,164,903	-	38,376	-	-	23,141,629
Buildings	72,384,788	1,468,300	-	9,238,851	-	1,210,154	84,302,093
Underground and Ground Plants	3,369,822	1,039,685	-	121,206	-	-	4,530,713
Facilities, Machinery and Equipment	87,651,386	13,482,231	-	17,130,128	43,735,705	20,909,710	182,909,160
Vehicles	9,270,006	7,721,276	(1,190,521)	-	(1,555,237)	117,519	14,363,043
Fixtures	2,497,858	2,739,061	(653,647)	71,475	-	104,304	4,759,051
Special Costs	43,995	38,086	-	-	-	-	82,081
Ongoing Investments	-	29,916,939	-	(26,778,608)	-	120,867	3,259,198
Total Cost	197,156,205	57,570,481	(1,844,168)	(178,572)	42,180,468	22,462,554	317,346,968
Accumulated Depreciation	January 1, 2020	Expenses for the Period	Disposals	Transfers	Revaluation and Reclassification	Subsidiary Acquisition	December 31, 2020
Buildings	(3,937,636)	(2,008,133)	19,619	-	19,128	(128,851)	(6,035,873)
Underground and Ground Plants	(30,639)	(82,698)	-	-	-	-	(113,337)
Facilities, Machinery and Equipment	(9,011,706)	(8,741,513)	-	-	-	(3,264,858)	(21,018,077)
Vehicles	(3,903,409)	(885,066)	713,756	-	770,483	(106,719)	(3,410,955)
Fixtures	(1,022,160)	(602,701)	551,638	-	-	(85,193)	(1,158,416)
Special Costs	(121)	(12,458)	-	-	-	-	(12,579)
Ongoing Investments	-	-	-	-	-	-	-
Total	(17,905,671)	(12,332,569)	1,285,013	-	789,611	(3,585,621)	(31,749,237)
Property, Plant and Equipment (Net)	179,250,534						285,597,731

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 17 – INTANGIBLE ASSETS**

Intangible assets as of March 31, 2021 and December 31, 2020 are as follows:

Description	January 1, 2021	Acquisitions	Disposals	Transfers	March 31, 2021
Rights (Computer Software)	545,121	212,410	-	-	757,531
Trademark Rights	324,724	40,931	-	-	365,655
Ongoing Investments	784,547	231,156	-	-	1,015,703
Total Cost	1,654,392	484,497	-	-	2,138,889

Accumulated Depreciation	January 1, 2021	Expenses for the Period	Disposals	Transfers	March 31, 2021
Rights (Computer Software)	(147,661)	(207,242)	-	-	(354,903)
Trademark Rights	(150,480)	(24,224)	-	-	(174,704)
Ongoing Investments	-	-	-	-	-
Total	(298,141)	(231,466)	-	-	(529,607)
Intangible Assets (Net)	1,356,251				1,609,282

Description	January 1, 2020	Acquisitions	Disposals	Transfers	December 31, 2020
Rights (Computer Software)	227,370	468,768	(151,017)	-	545,121
Trademark Rights	324,724	-	-	-	324,724
Ongoing Investments	-	784,547	-	-	784,547
Total Cost	552,094	1,253,315	(151,017)	-	1,654,392

Accumulated Depreciation	January 1, 2020	Expenses for the Period	Disposals	Transfers	December 31, 2020
Rights (Computer Software)	(68,207)	(230,471)	151,017	-	(147,661)
Trademark Rights	(118,008)	(32,472)	-	-	(150,480)
Ongoing Investments	-	-	-	-	-
Total	(186,215)	(262,943)	151,017	-	(298,141)
Intangible Assets (Net)	365,879				1,356,251

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 18 - PROVISIONS, CONTINGENT ASSETS AND LIABILITIES**

Short-term provisions as of March 31, 2021 and December 31, 2020 are as follows:

Short-term Provisions	March 31, 2021	December 31, 2020
Other Provisions	-	376,575
Provision for Fines Imposed by the Competition Authority	6,192,069	6,192,069
	6,192,069	6,568,644

(*) The letter no. E-13183850- 110.01.04-18808 of 11.01.2021, delivered to the Company and published on the website of the Competition Authority, states that pursuant to the decision no. 2101/18- 8 taken by of the Competition Authority on 07.01.2021 an administrative fine of 8,256,092.61 TRY was imposed on the Company due to violation of article 4 of the Law no. 4054, that a reasoned decision will also be served on the Company, and that the Company can apply to the Administrative Courts of Ankara within 60 days from the date of notification. The administrative fine can be paid with 25% discount (6,192,069.46 TRY) as per article 17(6) of the Misdemeanor Law no. 5326. A provision of 6,192,069 TRY was set aside for the discounted fine.

Collaterals, Pledges and Liens (CPL) Given by the Group	March 31, 2021	December 31, 2020
A. Total Amount of CPLs Given on Behalf of its Own Legal Personality	91,730,887	402,585,428
B. Total Amount of CPLs Given for Entities Included in Full Consolidation	34,791,500	15,795,000
C. Total Amount of CPLs Given to Secure Other Third Party Debt to Maintain Ordinary Course of Business	-	-
D. Total Amount of Other CPLs Given	-	-
i. Total Amount of CPLs Given for the Partner Company	-	-
ii. Total Amount of CPLs Given for the Other Group Companies Not Falling into the Scope of B and C	-	-
iii. Total Amount of CPLs Given for Third Parties Not Falling into the Scope of C	-	-
	126,522,387	418,380,428

The Group's receivables from Samsun Yem Sanayi ve Ticaret A.Ş. ("Samsun Yem"), Yemsel Tavukçuluk Hayvancılık Yem Hammaddeleri Sanayi ve Ticaret A.Ş. ("Yemsel") and Çakıroğlu Gıda Tarım Ürünleri Hayvancılık ve Yem Tavukçuluk Nakliyat Ticaret ve Sanayi A.Ş. ("Çakıroğlu") as of March 31, 2021 are as follows:

Company Title (*)	Trade Receivables	Advance Payments for Orders Placed	Total	Liens Received
Samsun Yem	1,232,128		1,232,128	700,000
Yemsel	1,293,727	3,042,014	4,335,741	6,000,000
Çakıroğlu	7,671,242		7,671,242	10,000,000
	10,197,097	3,042,014	13,239,111	16,700,000

(*) Referred to as Çakıroğlu Group collectively.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 18 – PROVISIONS, CONTINGENT ASSETS AND LIABILITIES (Continued)

Samsun Yem, Yemsel and Çakıroğlu applied to Samsun Commercial Court of First Instance requesting suspension of bankruptcy. The Group put a lien on the real estate of Samsun Yem, Yemsel and Çakıroğlu for its receivables detailed above. The lien put by the Group allows all receivables to be claimed from any encumbered real estate belonging to the Çakıroğlu Group. The Group ranks first in the lien on Samsun Yem and Çakıroğlu. It ranks second in the lien on Yemsel's real estate. Akbank T.A.Ş. ranks first in the lien on Yemsel's real estate. The total lien amount of Akbank T.A.Ş. is 6,000,000 TRY.

A notification was sent to Çakıroğlu Group regarding the payment of its debts. On 8 January 2016, a valuation was requested for the real estate. On December 29, 2016, an exploration was carried out for valuation with the court committee. On January 18, 2017, the experts submitted their reports to the court. A total value of 10,858,440.75 TRY was appraised for the encumbered real estate belonging to Çakıroğlu. A total value of 11,527,728.25 TRY was appraised for the encumbered real estate belonging to Yemsel. A total value of 263,249.19 TRY was appraised for the encumbered real estate belonging to Samsun Yem.

The decision to suspend the bankruptcy of Samsun Yem Sanayi ve Ticaret A.Ş. was rejected by the Samsun Commercial Court of First Instance on September 30, 2020. The Group requested a revaluation for the real estate. Samsun Commercial Court of First Instance issued a bankruptcy decision for Çakıroğlu and Yemsel on 30 September 2020.

The Group retained Varlık Real Estate Appraisal and Consultancy Company to issue real estate valuation reports for the first rank encumbered real estate of Çakıroğlu and Samsun Yem on February 17, 2021, and the total value of the two properties was appraised at 13,364,000 TRY. Since the fair values of the liens and real estate in the valuation reports were sufficient to cover the entire receivables, no provision was made.

FOOTNOTE 19 – PROVISIONS RELATED TO EMPLOYEE BENEFITS

Within the framework of the existing laws in Turkey, a member of staff of the Group whose job is terminated without valid reason after having completed one year of service, or who are called up for military service, who are deceased, who have completed 25 years in service for men and 20 years for women, or who have reached retirement age (58 for women, 60 for men), are entitled to severance pay. The amendments to the legislation on September 8, 1999 introduced certain transitional liabilities regarding creditable service period.

These payments are calculated based on 30-day salary at the full amount of 7.638,96 TRY as of March 31, 2021 using the rate as at the date of retirement or termination (December 31, 2020: 7,117.17 TRY). Severance pay provisions are calculated on a current basis and reflected in the financial statements. The provision is calculated based on the estimated present value of possible future liabilities due to the retirement of the Group's employees. The calculations are made in accordance with the severance pay cap announced by the Government.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 19 – PROVISIONS RELATED TO EMPLOYEE BENEFITS (Continued)**

Severance pay liability is calculated based on the estimated present value of possible future liabilities due to the retirement of the Group's employees. Pursuant to the TFRS, the Group is required to calculate its liabilities using actuarial valuation methods under its defined benefit plans. Accordingly, the actuarial assumptions that are to be used to calculate the total liabilities are specified below.

The main assumption is that the maximum liabilities for each year of service will increase in line with inflation. Accordingly, the applied discount rate refers to the expected real interest rate after adjustment for the effect of future inflation. Therefore, the liabilities as of March 31, 2021 in the attached financial statements are calculated based on the estimated present value of possible future liabilities due to the retirement of employees. The provision as at March 31, 2021 was calculated assuming a 10.75 percent annual inflation rate, a 16.25 percent interest rate and a 4.97 percent discount rate. (The provision as at December 31, 2020 was calculated assuming a 6.14 percent annual inflation rate, a 12.49 percent interest rate and a 5.98 percent discount rate.)

The Group's provision for severance pay as of March 31, 2021 and December 31, 2020 is as follows:

	March 31, 2021	December 31, 2020
Balance on January 1	2,564,363	2,055,194
Current Service Cost	405,726	949,356
Cost of Interest	259,112	137,646
Taken over	-	56,896
Payments within the Period	(361,967)	(753,072)
Actuarial Difference	76,437	118,343
End of Period Balance	2,943,671	2,564,363

Short-term provisions related to employee benefits as of March 31, 2021 and December 31, 2020 are as follows:

	March 31, 2021	December 31, 2020
Short-term Employee Benefits		
Provisions for Accumulated Leave	941,588	45,101
	941,588	45,101

Payables related to employee benefits as of March 31, 2021 and December 31, 2020 are as follows:

	March 31, 2021	December 31, 2020
Payables Related to Employee Benefits		
Social Security Premiums Payable	763,996	512,100
Payables to Personnel	1,922,948	1,306,209
	2,686,944	1,818,309

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 20 – OTHER ASSETS AND LIABILITIES**

Other current assets as of March 31, 2021 and December 31, 2020 are as follows:

Other Current Assets	March 31, 2021	December 31, 2020
VAT Carried Forward	16,365,424	13,506,837
Advance Payments to Personnel	517	-
Business Advance Payments	45,900	47,232
Other VAT	28,980	3,350
	16,440,821	13,557,419

Other short-term liabilities as of March 31, 2021 and December 31, 2020 are as follows:

Other Short-term Liabilities	March 31, 2021	December 31, 2020
Taxes and Funds Payable	1,783,922	1,258,749
Accrued Expenses	11,482,280	7,127,789
	13,266,202	8,386,538

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 21 – EQUITIES****Capital and Reserves**

The issued capital of the Company as of March 31, 2021 is 190,970,000 TRY. (one hundred ninety million nine hundred seventy thousand Turkish liras) This capital is divided into a total of 190,970,000 shares each with nominal value of 1 TRY, namely 22,035,000 Group A shares, 14,690,000 Group B shares and 154,245,000 Group C shares.

The Company's capital structure as of March 31, 2021 is as follows:

Shareholders	Number of Shares	Group	Percentage (%)	Amount
Fahrettin Ulusoy	10,283,000	A	5.38	10,283,000
	4,407,000	B	2.31	4,407,000
	-	C	-	-
	14,690,000		7.69	14,690,000
Nevin Ulusoy	1,469,000	A	0.77	1,469,000
	2,938,000	B	1.54	2,938,000
	27,589,237	C	14.45	27,589,237
	31,996,237		16.76	31,996,237
Onur Erhan Ulusoy	1,469,000	A	0.77	1,469,000
	4,407,000	B	2.31	4,407,000
	23,478,668	C	12.29	23,478,668
	29,354,668		15.37	29,354,668
Eren Günhan Ulusoy	8,814,000	A	4.62	8,814,000
	2,938,000	B	1.54	2,938,000
	37,925,691	C	19.86	37,925,691
	49,677,691		26.02	49,677,691
Mithat Denizcigil	215,518	C	0.11	215,518
	215,518		0.11	215,518
Kâmil Adem	60,887	C	0.03	60,887
	60,887		0.03	60,887
Publicly-held	64,975,000	C	34.02	64,975,000
Total	190,970,000		100.00	190,970,000

Upon the Board of Directors' decision on January 5, 2021, the Company increased its paid-in capital by 126 percent from 84,500,000.00 TRY (as of December 31, 2020) to 190,970,000.00 TRY through issuance of bonus shares.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 21 – EQUITIES (Continued)**

The Company's capital structure as of December 31, 2020 is as follows:

Shareholders	Number of Shares	Group	Percentage (%)	Amount
Fahrettin Ulusoy	4,550,000	A	5.38	4,550,000
	1,950,000	B	2.31	1,950,000
	-	C	-	-
	6,500,000		7.69	6,500,000
Nevin Ulusoy	650,000	A	0.77	650,000
	1,300,000	B	1.54	1,300,000
	12,207,627	C	14.45	12,207,627
	14,157,627		16.76	14,157,627
Onur Erhan Ulusoy	650,000	A	0.77	650,000
	1,950,000	B	2.31	1,950,000
	15,638,791	C	18.5	15,638,791
	18,238,791		21.58	18,238,791
Eren Günhan Ulusoy	3,900,000	A	4.62	3,900,000
	1,300,000	B	1.54	1,300,000
	16,781,279	C	19.86	16,781,279
	21,981,279		26.02	21,981,279
Kamil Adem	26,941	C	0.03	26,941
	26,941		0.03	26,941
Mithat Denizcigil	95,362	C	0.11	95,362
	95,362		0.11	95,362
Publicly-held	23,500,000	C	27.81	23,500,000
	84,500,000		100	84,500,000

According to the Turkish Commercial Code, legal reserves are divided into two, namely, primary and secondary legal reserves. 5% of the legal net profit is set aside as primary legal reserves until 20% of the paid-in capital of the Company is reached. Secondary legal reserves are set aside at 1/11 of all cash dividend distributions exceeding 5% of the Company's capital in cases where profit distribution is made in accordance with the CMB regulations, and at 1/10 of all cash dividend distributions exceeding 5% of the Company's capital in cases where profit distribution is made according to statutory records.

Publicly-held companies make their dividend distributions in accordance with the CMB's Dividend Communiqué no. II-19.1 published in the Official Gazette no 28891 on January 23, 2014.

Subsidiaries distribute their profits within the framework of the profit distribution policies to be formulated by their general assembly and in accordance with the provisions of the relevant legislation. The communiqué does not provide for a minimum distribution rate. Companies distribute dividends as determined in their articles of association or profit distribution policy. In addition, dividends can be paid in installments of equal or different amounts, and dividend advances can be distributed in cash based on the profit in the interim financial statements.

Unless the reserves required to be set aside in accordance with the Turkish Commercial Code and the dividend determined for the shareholders in the articles of association or the profit distribution policy are set aside, no decision can be made to set aside other reserves, to carry forward profits to the next year, and to distribute dividends to shareholders, members of the board of directors, subsidiary employees and non-shareholders, and no dividends can be distributed to the shareholders unless the dividend determined for them is paid in cash.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 21 – EQUITIES (Continued)**

Equity items as of March 31, 2021 and December 31, 2020 are as follows:

Equities	January 1 - March 31, 2021	January 1 - December 31, 2020
Paid-in Capital	190,970,000	84,500,000
Premiums (Discounts) Related to Shares	15,269,029	57,194,029
Other Comprehensive Income (Expenses) not to be Reclassified to Profit or Loss	61,342,033	61,443,837
<i>Property, Plant and Equipment Revaluation Difference (net)</i>	<i>62,149,360</i>	<i>62,149,360</i>
- Land and Buildings Revaluation Difference (net)	27,053,177	27,053,177
- Vehicles Revaluation Difference (net)	107,619	107,619
- Machinery, Facilities and Equipment Revaluation Difference (net)	34,988,564	34,988,564
<i>Actuarial Earnings/Losses Related to Employee Benefits</i>	<i>(807,327)</i>	<i>(705,523)</i>
Other Comprehensive Income (Expenses) to be Reclassified to Profit or Loss	24,725,806	15,353,588
<i>Foreign Currency Exchange Differences</i>	<i>24,725,806</i>	<i>15,353,588</i>
Reserves on Retained Earnings	10,102,037	7,726,207
Retained Earnings/Losses	91,369,991	115,008,531
Net Profit/Loss for the Period	11,461,834	43,282,290
	405,240,730	384,508,482

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 22 – REVENUE AND COST OF SALES**

The revenue and cost of sales for the periods ended March 31, 2021 and December 31, 2020 are as follows:

Revenue and Cost of Sales	January 1 - March 31, 2021	January 1 - March 31, 2020
Domestic Sales Income	389,537,547	203,775,906
Overseas Sales Income	1,085,711,392	856,322,073
Other Income	1,781,242	-
Gross Sales	1,477,030,181	1,060,097,979
Sales Returns	(923,437)	(923,243)
Sales Discounts	(269,900)	(67,440)
Net Sales	1,475,836,844	1,059,107,296
Cost of Merchandise Sold	(1,202,295,491)	(806,967,551)
Cost of Goods Sold	(198,174,725)	(188,243,503)
Cost of Services Sold	(2,098,858)	(2,075,022)
Gross Profit/Loss	73,267,770	61,821,220

The cost of sales for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Cost of Sales	January 1 - March 31, 2021	January 1 - March 31, 2020
Cost of Goods Sold	(198,174,725)	(188,243,503)
Cost of Merchandise Sold	(1,202,295,491)	(806,967,551)
Cost of Services Sold	(2,098,858)	(2,075,022)
Outsourced Benefits and Services	(137,946)	(931,150)
Personnel Expenses	(1,028,558)	(593,466)
Depreciation Expenses	(654,524)	(361,234)
Insurance Expenses	(122,758)	(86,317)
Transport Expenses	(78,849)	(88,227)
Other Expenses	(50,386)	(14,615)
Taxes, Duties and Charges	(25,837)	(13)
	(1,402,569,074)	(997,286,076)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 23 – OVERHEAD EXPENSES AND MARKETING COSTS**

Total operating expenses for the periods ended March 31, 2021 and March 31, 2020 are as follows:

	January 1 - March 31, 2021	January 1 - March 31, 2020
Overhead Expenses	(9,130,963)	(5,039,028)
Marketing Expenses	(24,946,292)	(13,057,053)
Research and Development Expenses	(13,116)	(45,073)
	(34,090,371)	(18,141,154)

Overhead expenses for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Overhead Expenses	January 1 - March 31, 2021	January 1 - March 31, 2020
Personnel Expenses	(3,893,936)	(2,314,357)
Consultancy Expenses	(954,303)	(1,021,702)
Outsourced Benefits and Services	(311,857)	(564,761)
Transport Expenses	(117,882)	(268,212)
Trade Fair Expenses	-	(224,001)
Other Expenses	(191,923)	(119,717)
Insurance Expenses	(27,511)	(111,269)
Donations and Grants	(136,250)	(97,986)
Taxes, Duties and Charges	(288,505)	(95,086)
Rent Expenses	-	(55,688)
Commission Expenses	(1,056)	(50,583)
Depreciation Expenses	(2,763,417)	(49,635)
Training and Publication Expenses	(44,822)	(45,231)
Advertisement Expenses	(40,162)	(20,800)
Depreciation Expenses of Leases	(206,218)	-
Maintenance and Repair Expenses	(43,727)	-
Accommodation Expenses	(30,607)	-
Overdue Fines	(28,000)	-
Notary Expenses	(25,974)	-
Bank Transfer and Collection Expenses	(24,813)	-
	(9,130,963)	(5,039,028)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 23 – OVERHEAD EXPENSES AND MARKETING EXPENSES (Continued)**

Marketing expenses for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Marketing Expenses	January 1 - March 31, 2021	January 1 - March 31, 2020
Shipping Expenses	(5,376,486)	(6,915,878)
Export Expenses	(15,056,103)	(2,924,638)
Personnel Expenses	(2,387,423)	(1,177,230)
Commission Expenses	(199,231)	(481,245)
Tax, Duty and Charge Expenses	(7,567)	(429,720)
Outsourced Benefits and Services	(807,599)	(401,516)
Insurance Expenses	(121,979)	(166,274)
Depreciation Expenses	(32,478)	(153,420)
Trade Fair Expenses	(157,634)	(145,837)
Vehicle Expenses	(288,720)	(104,302)
Other Expenses	(94,329)	(71,198)
Food Expenses	(85,347)	(66,712)
Transport Expenses	(12,955)	(14,217)
Consultancy Expenses	(7,115)	(4,866)
Bank Transfer and Collection Expenses	(8,039)	-
Overdue Fines	(6,930)	-
Rent Expenses	(135,505)	-
Accommodation Expenses	(11,364)	-
Depreciation Expenses of Leases	(149,488)	-
	(24,946,292)	(13,057,053)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 24 – OTHER OPERATING INCOME AND EXPENSES**

Other operating income for the periods ended March 31, 2021 and March 31, 2020 is as follows:

Other Operating Income	January 1 - March 31, 2021	January 1 - March 31, 2020
Exchange Rate Difference Income Related to Trade Receivables and Payables	53,687,939	41,220,789
Due Date Difference Income	4,316,659	3,108,254
Income from Returned Expenses	291,398	1,116,989
Licensed Warehouse Rent Support	1,283,721	789,090
Compensation Income	29,959	630,316
Service Reflection Income	1,894,345	630,265
Provisions No Longer Required	5,130,591	355,845
Other Income	1,319,599	336,150
Income from Law no. 5510 and Law no. 6661	333,582	294,529
Balance Collection Income	150,168	179,210
Price Difference Income	70,943	109,069
Income from Incentives and Subsidies	127,899	24,378
Rediscount Interest Income	6,705,993	-
Previous Years' Income	140,347	-
	75,483,143	48,794,884

Other operating expenses for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Other Operating Expenses	January 1 - March 31, 2021	January 1 - March 31, 2020
Exchange Difference Expenses	(19,074,231)	(10,061,113)
Due Date Difference Expenses	(4,844,782)	(3,255,296)
Provision Expenses	(4,006,771)	(822,105)
Returned Expenses	(136,473)	(565,492)
Balance Collection Expenses	(361,849)	(395,314)
Price Difference Expenses	(1,006,866)	(183,401)
Other Expenses	(507,195)	(163,612)
Rediscounted Interest Expenses	(4,911,956)	-
Previous Period Expenses and Losses	(17,344)	-
	(34,867,467)	(15,446,333)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 25 – INCOME FROM INVESTING ACTIVITIES**

Income from investing activities for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Income from Investing Activities	January 1 - March 31, 2021	January 1 - March 31, 2020
Fixed Asset Sale Income	283,538	174,698
Sale and Lease Back Income	-	215,405
	283,538	390,103

Impairment Earnings/Losses and Cancelled Impairment Losses as per TFRS 9 are as follows:

	January 1 - March 31, 2021	January 1 - March 31, 2020
Expected Credit Loss and Other Provisions	(266,588)	(196,760)
	(266,588)	(196,760)

FOOTNOTE 26 – FINANCE INCOME AND EXPENSES

Finance income for the periods ended March 31, 2021 and March 31, 2020 is as follows:

Finance Income	January 1 - March 31, 2021	January 1 - March 31, 2020
Interest Income	3,765,532	2,061,709
Foreign Exchange Profits	57,968,485	23,396,425
Derivative Financial Instruments Income	9,347,816	1,828,197
Profit on Sale of Securities	9,045,150	120,570
Fair Value Differences of Derivative Financial Instruments	5,562,000	18,414,875
	85,688,983	45,821,776

Finance expenses for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Finance Expenses	January 1 - March 31, 2021	January 1 - March 31, 2020
Foreign Exchange Losses	(101,360,394)	(82,009,085)
Finance Expenses	(22,925,430)	(12,156,965)
Derivative Financial Instruments Expenses	(8,645,207)	(3,085,779)
Fair Value Differences of Derivative Financial Instruments	(17,419,315)	-
Finance Expenses Arising from Leasing Liability	(53,907)	-
	(150,404,254)	(97,251,829)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 27 – INCOME TAXES

Corporate tax

As of December 31, 2021, the corporate tax rate applied in Turkey is 20 percent. However, as per the amendment to the Corporate Tax Law that entered into force after being published in the Official Gazette no. 31462 on April 22, 2021, the corporate tax rate in Turkey, which is 20 percent as of March 31, 2021, will be 25 percent in 2021 and 23 percent in 2022. This will be effective from January 1, 2021.

In addition, the amendment to the Law no. 5520 on Corporate Tax reduced the exemption rate of 75% for the proceeds from the sale of property, which has been in the assets for at least two years, to 50%, starting from January 1, 2018.

According to Turkish tax legislation, financial losses can be carried forward for a maximum period of five years to be set off against the future income of the entity. Financial losses, however, cannot be set off from the previous years' profits.

The Company's subsidiary Rolweg is operating in Switzerland. Income tax in Switzerland is 12.5 percent

Income tax withholding

There is no practice of reaching an agreement with the tax authority under the tax legislation of Turkey. Corporate tax returns are submitted within four months following the month in which the accounting period ends. Competent authorities related to tax investigations can examine the tax returns and the accounting records on which they are based within five years of the accounting period, and can carry out assessments as a consequence of their findings.

Dividend distributions are subject to a withholding tax obligation, which accrues in the dividend payment period. Excluding those distributed to limited taxpayer institutions that earn income through a workplace or permanent representative office in Turkey or to the resident institutions in Turkey, dividend payments are subject to a withholding tax rate of 15 percent. The withholding tax rates specified in the related treaties for the avoidance of double taxation are also taken into account in imposing withholding tax to limited taxpayer institutions and natural persons. The allocation of the previous years' profit to the capital is not considered dividend distribution, and therefore is not subject to withholding tax.

The provisions on transfer pricing in Turkey are contained in Article 13 "Disguised Profit Distribution through Transfer Pricing" of the Corporate Tax Law. The Communiqué on disguised profit distribution through transfer pricing of November 18, 2007 sets forth the details of this practice.

In the event of the taxpayer purchasing or selling goods or services to related persons in return for a price or value that is against the arm's length principle, the earnings are considered disguised profits, distributed, wholly or in part, through transfer pricing. Such disguised profits distributed through transfer pricing are deemed to be non-tax-deductible expenses for corporate tax.

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 27 – INCOME TAXES (Continued)****Deferred tax assets and liabilities**

The Company calculates its taxable assets and liabilities taking into account the effect of temporary differences resulting from different assessment of balance sheet items in statutory financial statements and those prepared pursuant to the TFRS. Such temporary differences usually arise from recognition of income and expenses in different reporting periods pursuant to the TFRS and tax laws.

The Group's deferred tax assets and liabilities as of March 31, 2021 are as follows:

March 31, 2021 - Deferred Tax Assets	Temporary Differences	Deferred Tax Effect
Bad Debt	6,922,741	1,387,677
Adjustment for Receivables from Personnel	69,015	13,803
Adjustment for Advance Payments Made	3,225,609	645,122
Value Adjustment for Property, Plant and Equipment and Intangible Assets	5,535,435	1,454,320
Inventory Impairment Expense and Other Inventory Adjustments	4,700,118	940,024
Adjustment for Amortized Cost of Receivables	2,714,447	544,495
Adjustment for Amortized Cost of Payables	2,792,663	693,795
Interest Accrual Adjustment	104,100	16,372
Exchange Rate Difference	1,408,108	352,027
Adjustment for Loans	-	3,933,357
Provisions for Unused Leave Days	721,921	166,042
Provisions for Severance Pay	747,359	176,912
Letter of Credit Interest Adjustment	9,476,181	2,369,045
Change in Accounting Policy	541,307	75,315
Other Adjustments	44,550	1,321,792
Severance Pay Actuarial Difference	1,017,137	209,689
Investment Allowance	18,324,661	3,968,206
	58,345,352	18,267,993

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 27 – INCOME TAXES (Continued)**

March 31, 2021 - Deferred Tax Liabilities	Temporary Differences	Deferred Tax Effect
Effect of Property, Plant and Equipment Valuation Associated with Equities (Vehicles)	134,524	26,905
Effect of Property, Plant and Equipment Valuation Associated with Equities (Machinery, Facilities and Equipment)	55,714,491	11,142,898
Effect of Property, Plant and Equipment Valuation Associated with Equities (Lands and Buildings)	30,396,829	3,343,651
Inventory Impairment Expense and Other Inventory Adjustments	6,125,356	1,530,427
Adjustment for Amortized Cost of Receivables	626,269	155,903
Derivative Instrument Fair Value Difference Adjustment	8,959,146	2,077,660
Interest Accrual Adjustment	3,737	934
Bad Debt	5,745,156	1,436,159
Adjustment for Loans	8,121,104	2,030,276
Leasing liability	9,511	2,378
Other Adjustments	1,025,824	256,180
Adjustment for Amortized Cost of Payables	2,859,888	573,783
Property, Plant and Equipment and Intangible Assets Depreciation Difference	15,775,494	3,156,449
Provisions for Severance Pay	5,723,722	1,150,319
Investment Allowance	3,160,970	632,194
Adjustment for Receivables from Personnel	120	24
	144,382,141	27,516,140

The Group's deferred tax assets and liabilities as of December 31, 2020 are as follows:

December 31, 2020 - Deferred Tax Assets	Temporary Differences	Deferred Tax Effect
Bad Debt	6,860,167	1,372,033
Adjustment for Receivables from Personnel	68,895	13,779
Adjustment for Advance Payments Made	3,225,609	645,122
Value Adjustment for Property, Plant and Equipment and Intangible Assets	1,459,578	563,942
Inventory Impairment Expense and Other Inventory Adjustments	4,700,118	940,024
Adjustment for Amortized Cost of Receivables	2,682,353	536,471
Interest Accrual Adjustment	81,860	16,372
Adjustment for Loans	19,666,785	3,933,357
Other Adjustments	6,985,420	1,397,086
Severance Pay Actuarial Difference	885,447	179,924
Investment Allowance	18,324,661	3,968,206
	64,940,893	13,566,316

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 27 – INCOME TAXES (Continued)**

December 31, 2020 - Deferred Tax Liabilities	Temporary Differences	Deferred Tax Effect
Effect of Property, Plant and Equipment Valuation Associated with Equities (Vehicles)	134,524	26,905
Effect of Property, Plant and Equipment Valuation Associated with Equities (Machinery, Facilities and Equipment)	55,714,491	11,142,898
Effect of Property, Plant and Equipment Valuation Associated with Equities (Lands and Buildings)	30,396,829	3,343,651
Derivative Instrument Fair Value Difference Adjustment	3,242,525	648,505
Adjustment for Amortized Cost of Payables	2,823,782	564,756
Property, Plant and Equipment and Intangible Assets Depreciation Difference	14,161,518	2,832,304
Provisions for Severance Pay	5,661,992	1,131,747
	112,135,661	19,690,766
Deferred Tax Liability	January 1 - March 31, 2021	January 1 - December 31, 2020
Balance on January 1	(6,124,450)	1,689,783
Recognized in profit or loss	(3,154,106)	3,300,607
Taken over by GK Tarım	-	822,933
Property, Plant and Equipment Revaluation Reserve and Actuarial Difference Deferred Tax Effect	30,409	(11,937,773)
	(9,248,147)	(6,124,450)
	January 1 - March 31, 2021	January 1 - March 31, 2020
Tax Income/Expense for the Period	(651,541)	(2,022,467)
Deferred Tax Income/Expense	(3,154,106)	(4,563,874)
	(3,805,647)	(6,586,341)
Tax Liability for the Current Period Profit	January 1 - March 31, 2021	January 1 - December 31, 2020
Provisions for Tax on Current Period Profit and Other Legal Liabilities	130,056	371,748
Prepaid Tax and Other Liabilities Related to the Current Period Profit	(130,056)	(310,523)
	-	61,225

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 28 – EARNINGS PER SHARE**

Earnings per share for the periods ended March 31, 2021 and March 31, 2020 are as follows:

	January 1 - March 31, 2021	January 1 - March 31, 2020
Net Profit/Loss for the Period	11,461,834	19,432,780
Weighted Average Number of Ordinary Shares in Circulation	190,970,000	82,482,088
Earnings Per Share	0.0600	0.2356

FOOTNOTE 29 – RELATED PARTY DISCLOSURES

Related party disclosures for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Trade Receivables from Related Parties	March 31, 2021	December 31, 2020
GFC Denizcilik ve Ticaret A.Ş.	789,819	850,487
Unay Un San. ve Tic. A.Ş.	63,787	18,388
Ulusoy Çay Gıda San. ve Tic. A.Ş.	19,948	27,088
Ulusoy Petrol Ürünleri Tic. A.Ş.	-	8,699
	873,554	904,662

Notes Receivable from Related Parties	March 31, 2021	December 31, 2020
Unay Un San. ve Tic. A.Ş.	603,280	480,049
	603,280	480,049

Trade Payables to Related Parties	March 31, 2021	December 31, 2020
Unay Un San. ve Tic. A.Ş.	5,262,951	-
Ulusoy Petrol Ürünleri Tic. A.Ş.	107,945	31,538
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	66,171	58,339
	5,437,067	89,877

Other Payables to Related Parties	March 31, 2021	December 31, 2020
Unay Un San. ve Tic. A.Ş.	14,592,129	14,959,964
	14,592,129	14,959,964

Advance Payments for Orders Placed with Related Parties	March 31, 2021	December 31, 2020
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	30,021	-
Unay Un San. ve Tic. A.Ş.	-	415,012
	30,021	415,012

Sales Income from Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Unay Un San. ve Tic. A.Ş.	8,068,000	1,570,993
Ulusoy Çay Gıda San. ve Tic. A.Ş.	-	9,000
	8,068,000	1,579,993

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 29 – RELATED PARTY DISCLOSURES (Continued)**

Related party disclosures for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Purchases from Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Ulusoy Çay Gıda San. ve Tic. A.Ş.	6,611	2,782
Unay Un San. ve Tic. A.Ş.	74,379,802	6,839,178
Ulusoy Petrol Ürünleri Tic. A.Ş.	601,598	404,207
GK Tarım Ürünleri Depoculuk A.Ş.	-	152,123
GFC Denizcilik ve Ticaret A.Ş.	7,419	-
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	413,479	-
	75,408,909	7,398,290
Other Income from Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Unay Un San. ve Tic. A.Ş.	80,691	250,351
	80,691	250,351
General Production and Service Expenses to Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Unay Un San. ve Tic. A.Ş.	11,192	7,206
Ulusoy Petrol Ürünleri Tic. A.Ş.	15,145	11,565
	26,337	18,771
Marketing Expenses to Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Unay Un San. ve Tic. A.Ş.	102,230	27,393
Ulusoy Petrol Ürünleri Tic. A.Ş.	151,250	99,979
GFC Denizcilik ve Ticaret A.Ş.	-	2,134
	253,480	129,506
Overhead Expenses to Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Ulusoy Petrol Ürünleri Tic. A.Ş.	50,514	26,372
Unay Un San. ve Tic. A.Ş.	1,664	-
	52,178	26,372

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 29 – RELATED PARTY DISCLOSURES (Continued)**

Related party disclosures for the periods ended March 31, 2021 and March 31, 2020 are as follows:

Other Expenses to Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
GFC Denizcilik Ticaret A.Ş.	-	1,777
Unay Un San. ve Tic. A.Ş.	25,564	45,306
Ulusoy Petrol Ürünleri Tic. A.Ş.	17,501	-
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	7,783	-
	50,848	47,083

Finance Expenses to Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Unay Un San. ve Tic. A.Ş.	566,271	31,596
	566,271	31,596

Finance Income from Related Parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Unay Un San. ve Tic. A.Ş.	1,382,905	1,249,524
	1,382,905	1,249,524

The Group's senior management consists of board members, general manager and department managers. The benefits and fees provided by the Group to its senior management as of March 31, 2021 are 722,412 TRY (December 31, 2020: 1,829,640 TRY).

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 30 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS****Credit Risk**

March 31, 2021	Receivables				Bank Deposits deposits	Derivative instruments	Other
	Trade receivables		Other Receivables				
	Related party	Other party	Related party	Other party			
Maximum credit risk as of the date of the report (A+B+C+D+E+F)	1,476,834	803,951,209	-	9,796,833	446,572,654	56,383,954	75,841,614
- The portion of the maximum risk hedged by collateral, etc.							
A. Net book value of the financial assets that are not overdue or impaired	1,476,834	804,100,079	-	9,796,833	446,572,654	56,383,954	75,841,614
B. Net book value of the financial assets the conditions of which were renegotiated, or otherwise deemed to be overdue or impaired	-	-	-	-	-	-	-
C. Net book value of the financial assets that are overdue, but not impaired	-	-	-	-	-	-	-
- The portion hedged by collaterals, etc.	-	-	-	-	-	-	-
D. Net book value of the assets that are impaired	-	-	-	-	-	-	-
- Past due (gross book value)	-	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-	-
- Undue (gross book value)	-	7,340,638	-	-	-	-	-
- Impairment (-)	-	(7,340,638)	-	-	-	-	-
E. Components involving off-balance sheet credits	-	-	-	-	-	-	-
F. Expected Credit Loss	-	(148,870)	-	-	-	-	-

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 30 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Continued)

Credit Risk (Continued)

December 31, 2020	Receivables				Bank Deposits deposits	Derivative instruments	Other
	Trade receivables		Other Receivables				
	Related party	Other party	Related party	Other party			
Maximum credit risk as of the date of the report (A+B+C+D+E+F)	1,384,711	439,318,203	-	15.144.060	309,093,561	10,668,553	106,101,153
- The portion of the maximum risk hedged by collateral, etc.							
A. Net book value of the financial assets that are not overdue or impaired	1,384,711	439,318,203	-	15.144.060	309,093,561	10,668,553	106,101,153
B. Net book value of the financial assets the conditions of which were renegotiated, or otherwise deemed to be overdue or impaired	-	-	-	-	-	-	-
C. Net book value of the financial assets that are overdue, but not impaired	-	-	-	-	-	-	-
- The portion hedged by collaterals, etc.	-	-	-	-	-	-	-
D. Net book value of the assets that are impaired	-	-	-	-	-	-	-
- Past due (gross book value)	-	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-	-
- Undue (gross book value)	-	7,521,114	-	-	-	-	-
- Impairment (-)	-	(7,521,114)	-	-	-	-	-
E. Components involving off-balance sheet credits	-	-	-	-	-	-	-
F. Expected Credit Loss	-	-	-	-	-	-	-

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 30 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Continued)****Liquidity risk**

March 31, 2021						
Non-derivative Financial Liabilities	Book Value	Total cash outflow under the Contract (I+II+III+IV)	Less than 3 months (I)	3–12 months (II)	1–5 years (III)	More than 5 years (IV)
Bank Loans	1,112,479,074	1,112,479,074	170,022,214	680,088,856	241,559,584	20,808,420
Trade Payables	662,514,434	662,514,434	-	662,514,434	-	-
Other Payables	15,078,921	15,078,921	-	15,078,921	-	-
Total Liabilities	1,790,072,429	1,790,072,429	170,022,214	1,357,682,211	241,559,584	20,808,420

December 31, 2020						
Non-derivative Financial Liabilities	Book Value	Total cash outflow under the Contract (I+II+III+IV)	Less than 3 months (I)	3–12 months (II)	1–5 years (III)	More than 5 years (IV)
Bank Loans	819,279,613	819,279,613	92,746,556	433,375,141	263,818,680	29,339,236
Trade Payables	392,005,623	392,005,623	-	392,005,623	-	-
Other Payables	15,479,323	15,479,323	-	15,479,323	-	-
Total Liabilities	1,226,764,559	1,226,764,559	92,746,556	840,860,087	263,818,680	29,339,236

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)

FOOTNOTE 30 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Continued)

Foreign Currency Risk

	March 31, 2021				December 31, 2020		
	TRY equivalent	USD	EUR	Other	TRY equivalent	USD	EUR
1. Trade receivables	604,424,322	71,834,675	513,638	12,100,000	366,624,547	49,384,032	457,494
2a. Monetary financial assets (including cash bank accounts)	378,902,332	43,057,836	1,219,306	961,744	305,316,284	41,155,663	356,702
2b. Non-monetary financial assets	-	-	-	-	-	-	-
3. Other	20,651,022	2,480,365	-	-	-	-	-
4. Current assets (1+2+3)	1,003,977,676	117,372,876	1,732,944	13,061,744	671,940,831	90,539,695	814,196
5. Trade receivables	-	-	-	-	-	-	-
6a. Monetary financial assets	-	-	-	-	34,500,221	4,699,982	-
6b. Non-monetary financial assets	-	-	-	-	-	-	-
7. Other	-	-	-	-	6,356,983	633,802	189,229
8. Non-current assets (5+6+7)	-	-	-	-	40,857,204	5,333,784	189,229
9. Total assets (4+8)	1,003,977,676	117,372,876	1,732,944	13,061,744	712,798,035	95,873,479	1,003,425
10. Trade payables	220,265,025	26,369,543	32,897	-	385,739,937	52,240,430	251,897
11. Financial liabilities	325,638,316	37,278,376	1,502,783	-	172,217,007	20,692,369	2,256,317
12a. Other monetary liabilities	15,157,538	1,817,276	-	-	13,679,449	1,506,043	291,338
12b. Other non-monetary liabilities	-	-	-	-	-	-	-
13. Short-term liabilities (10+11+12)	561,060,879	65,465,195	1,535,680	-	571,636,393	74,438,842	2,799,552
14. Trade payables	-	-	-	-	-	-	-
15. Financial liabilities	104,436,710	12,521,186	-	-	125,782,130	17,135,363	-
16 a. Other monetary liabilities	-	-	-	-	260	35	-
16 b. Other non-monetary liabilities	-	-	-	-	-	-	-
17. Long-term liabilities (14+15+16)	104,436,710	12,521,186	-	-	125,782,390	17,135,398	-
18. Total liabilities (13+17)	665,497,589	77,986,381	1,535,680	-	697,418,783	91,574,240	2,799,552
19. Net asset/liability position of off-balance sheet derivative financial instruments (19a-19b)	72,404,672	8,696,422	-	-	75,253,497	8,000,000	1,835,000
19a. Total amount of hedged assets	72,404,672	8,696,422	-	-	75,253,497	8,000,000	1,835,000
19b. Total amount of hedged liabilities	-	-	-	-	-	-	-
20. Net foreign currency asset/liability position (9-18+19)	410,884,759	48,082,917	197,264	13,061,744	90,632,749	12,299,239	38,873
21. Total fair value of financial instruments used for foreign currency hedging (1+2a+3+5+6a-10-11 -12a-14-15-16a)	338,480,087	39,386,495	197,264	13,061,744	15,379,252	4,299,239	1,796,127

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 30 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Continued)****Foreign Currency Risk (Continued)**

The following table shows the Group's sensitivity to a 10 percent increase and decrease in the exchange rates. This sensitivity analysis covers only the open foreign currency monetary items at the end of the period, and shows the effects of a 10 percent change in foreign currency rates on the items. Positive values refer to increases in profit/loss and other equity items.

Statement of exchange rate sensitivity analysis				
March 31, 2021				
	Profit/loss		Equities	
	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION
In the event of USD increasing/decreasing 10% in value against TRY				
1- Net assets/liabilities in USD	32,675,428	(32,675,428)	32,675,428	(32,675,428)
2- The portion hedged against the USD risk (-)				
3- USD net effect (1+2)	32,675,428	(32,675,428)	32,675,428	(32,675,428)
In the event of EUR increasing/decreasing 10% in value against TRY				
4- Net assets/liabilities in EUR	190,000	(190,000)	190,000	(190,000)
5- The portion hedged against the EUR risk (-)				
6- EUR net effect (4+5)	190,000	(190,000)	190,000	(190,000)
In the event of GBP increasing/decreasing 10% in value against TRY				
7- Other net assets/liabilities	982,580	(982,580)	982,580	(982,580)
8- The portion hedged against other risks (-)				
9- Other net effect (7+8)	982,580	(982,580)	982,580	(982,580)
Total (3+6+9)	33,848,008	(33,848,008)	33,848,008	(33,848,008)

Statement of exchange rate sensitivity analysis				
December 31, 2020				
	Profit/loss		Equities	
	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION
In the event of USD increasing/decreasing 10% in value against TRY				
1- Net assets/liabilities in USD	3,155,856	(3,155,856)	3,155,856	(3,155,856)
2- The portion hedged against the USD risk (-)				
3- USD net effect (1+2)	3,155,856	(3,155,856)	3,155,856	(3,155,856)
In the event of EUR increasing/decreasing 10% in value against TRY				
4- Net assets/liabilities in EUR	(1,617,933)	1,617,933	(1,617,933)	1,617,933
5- The portion hedged against the EUR risk (-)				
6- EUR net effect (4+5)	(1,617,933)	1,617,933	(1,617,933)	1,617,933
Total (3+6)	1,537,923	(1,537,923)	1,537,923	(1,537,923)

ULUSOY UN SANAYİ VE TİCARET A.Ş.

Footnotes to the Consolidated Financial Statements as of March 31, 2021

*(Amounts are expressed in Turkish lira ("TRY") unless otherwise stated.)***FOOTNOTE 31 – FINANCIAL INSTRUMENTS (FAIR VALUE DISCLOSURES AND OTHER DISCLOSURES CONCERNING HEDGE ACCOUNTING)****Fair Value of Financial Instruments**

Based on the source of valuation inputs of each financial instrument class, the Group categorizes the financial instruments recognized at fair value according to the three-level hierarchy.

Level 1: Valuation techniques using quoted prices in active markets for identical assets or liabilities that the Group has the ability to access at the measurement date;

Level 2: Other valuation techniques involving inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly;

Level 3: Valuation techniques using unobservable inputs for the assets or liability.

Financial Assets (March 31, 2021)	Level 1	Level 2	Level 3
Derivative assets	-	56,383,954	-
Short-term Financial Investments	65,334,830	-	-
Financial liabilities (March 31, 2021)	Level 1	Level 2	Level 3
Derivative liabilities	-	15,157,538	-
Short-term Financial Investments	-	-	-
Financial Assets (December 31, 2020)	Level 1	Level 2	Level 3
Derivative assets	-	10,668,553	-
Short-term Financial Investments	32,104,780	-	-
Financial Liabilities (December 31, 2020)	Level 1	Level 2	Level 3
Derivative liabilities	-	2,017,984	-
Short-term Financial Investments	-	-	-

FOOTNOTE 32 – EVENTS AFTER THE REPORTING PERIOD

As per the amendment to the Corporate Tax Law that entered into force after being published in the Official Gazette no. 31462 on April 22, 2021, the corporate tax rate in Turkey, which is 20 percent as of March 31, 2021, will be 25 percent in 2021 and 23 percent in 2022. This will be effective from January 1, 2021.